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ABSTRACT OF DISSERTATION
INFLAMMATORY INTERACTIONS AND SECRETION
IN CARDIAC REMODELING

Heart failure contributes to nearly 60,000 deaths per year in the USA and is often
caused by hypertension and preceded by the development of left ventricular
hypertrophy (LVH). LVH is usually accompanied by intensive interstitial and perivascular
fibrosis which may contribute to arrhythmogenic sudden cardiac death. Emerging
evidence indicates that LV dysfunction in patients and animal models of cardiac
hypertrophy is closely associated with perivascular inflammation.
To investigate the role of perivascular inflammation in coronary artery remodeling and
cardiac fibrosis during hypertrophic ventricular remodeling, we used a well-established
mouse model of pressure-overload-induced LVH: transverse aortic constriction (TAC).
Early perivascular inflammation was indicated by accumulation of macrophages and T
lymphocytes 24 hours post-TAC and which peaked at day 7. Coronary luminal platelet
deposition was observed along with macrophages and lymphocytes at day 3. Also, LV
protein levels of VEGF and MCP-1 were significantly increased. Consistent with
lymphocyte accumulation, cardiac expression of IL-10 mRNA was elevated.
Furthermore, circulating platelet-leukocyte aggregates tended to be higher after TAC,
compared to sham controls. Platelets have been shown to modulate perivascular
inflammation and may facilitate leukocyte recruitment at sites of inflamed endothelium.
Therefore, we investigated the impact of thrombocytopenia in the response to TAC.
Immunodepletion of platelets decreased early perivascular accumulation of T
lymphocytes and IL-10 mRNA expression, and altered subsequent coronary artery
remodeling. The contribution of lymphocytes was examined in Rag1-/- mice, which
displayed significantly more intimal hyperplasia and perivascular fibrosis compared to
wild-type mice following TAC. Collectively, our studies support a role of early
perivascular accumulation of platelets and T lymphocytes in pressure overload-induced
inflammation which will contribute to long-term LV remodeling.
One potential mechanism for inflammatory cells to modulate their environment and
affect surrounding cells is through release of cargo stored in granules. To determine the
contribution of granule release from inflammatory cells in the development of LVH, we
used Unc13dJinx (Jinx) mice, which contain a single point mutation in Unc13d gene
resulting in defects in Munc13-4. Munc13-4 is a limiting factor in vesicular priming and
fusion during granule secretion. Therefore, Jinx mice have defects in degranulation of
platelets, NK cells, cytotoxic T lymphocytes, neutrophils, mast and other cells. With the
use of bone marrow transplantation, Jinx chimeric mice were created to determine
whether the ability of hematopoietic cells to secrete granule contents affects the
development of LVH. Wild-type mice (WT) that were transplanted with WT bone
marrow (WT>WT) and WT mice that received Jinx bone marrow (Jinx>WT) developed

LVH and a classic fetal reprogramming response early after TAC (7 days), but at later
times (5 weeks), Jinx>WT mice failed to sustain the cardiac hypertrophic response
observed in WT>WT mice. No difference in cardiac fibrosis was observed at early or late
times. Repetitive injection of WT platelets or platelet releasate restored cardiac
hypertrophy in Jinx>WT mice. These results suggest that sustained LVH in the setting of
pressure overload depends on factor(s) secreted, likely from platelets.
In conclusion, our studies demonstrate that platelets and lymphocytes are involved in
early perivascular inflammation post-TAC, which may contribute to later remodeling in
the setting of LVH. Factors released from hematopoietic cells, including platelets, in a
Munc13-4-dependent manner are required to promote cardiac hypertrophy. These
findings focus attention on modulating perivascular inflammation and targeting granule
cargo release to prevent the development and consequences of LVH.
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CHAPTER 1: INTRODUCTION
SECTION 1: Cardiac Hypertrophy and Perivascular Inflammation
Left Ventricular Hypertrophy (LVH): LVH is a compensatory mechanism for the heart to work
more effectively when greater workloads are required in the setting of mechanical or oxidized
stress, overactive sympathetic drive, or as a consequence of genetic abnormalities.
Physiological LVH can happen in the short-term during pregnancy and exercise, and is reversible
when the physical demands disappear [1]. In the presence of pathological signals,
compensatory increase of cardiomyocyte size and number cannot preserve cardiac contractility
persistently and might proceed to dilated hypertrophy [2,3]. The latter impaired contractility
and chamber dilation might be due to other remodeling (i.e.. Imbalance of extracellular matrix
(ECM) turnover and fibrosis formation) and myocyte apoptosis. LVH can also be influenced by
other factors, such as age and gender [4].
The major cause of LVH is systemic hypertension and application of anti-hypertensive
medication may reverse LVH and improve the clinical outcomes [3-6]. Nearly one-third of
American adults have hypertension, of which 20% – 60% will develop LVH and may progress to
heart failure. Heart failure contributes to nearly 60,000 deaths per year in the USA. Given that
LVH is a strong risk factor of heart failure and an independent predictor of cardiovascular death
[7,8], a better understanding of the underlying mechanisms is needed for prevention and
treatment.
Pathological Changes that Occur During Development of LVH
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Myocardial Hypertrophy Myocardial hypertrophy is described as the increase of the
cardiomyocyte size and number in response to stresses, such as the increase of intracavitary
pressure and mechanical stretch. Typically, LVH has two subtypes: concentric hypertrophy and
eccentric hypertrophy. Concentric hypertrophy is usually induced by pressure-overload and is
characterized by significant increase of LV wall thickness and force generation, and impaired
filling state due to stiffness (diastolic dysfunction). Eccentric hypertrophy is mainly caused by
volume-overload and is characterized by moderate increase of wall thickness with impressive
chamber dilation (systolic dysfunction). In the compensated state, an increase in diameter of
cardiomyocytes and number of sarcomeres in parallel elevates the contractile force generated
per cell to meet the required cardiac output. However, the compensatory increase of cardiac
output cannot last indefinitely and will gradually precede to life-threatening cardiac episodes,
such as myocardial infarction (MI), arrhythmia, and heart failure. The decompensation could be
due to (1) inadequate oxygen and nutrition supply (2) reduced myocardial capillary density, (3)
reduced space for coronary artery vasodilatation and (4) capillary compression, which together
contribute to myocardial ischemia and make the hypertrophic cardiomyocytes more vulnerable
[9,10]. Also, cardiomyocytes add in series in the decompensated state which contributes to
chamber dilation, reduced myocyte contractility and cardiac output. The molecular mechanisms
of cardiac hypertrophy have been widely studied in the context of membrane-bound receptor
activation in response to mechanical stress, oxidative stress, and other neurohormonal factors.
The resulting downstream signaling will induce myocardial re-expression of a fetal gene
program (i.e. atrial natriuretic peptide, brain natriuretic peptide, β-myosin heavy chain and αskeletal muscle actin) and abnormal increase in synthesis of myocardial proteins, which will
2

ultimately leads to pathological growth and proliferation of cardiomyocytes [5,11].
Myocardial Fibrosis: Apart from myocardial hypertrophy, hypertensive LV remodeling is also
associated with a disproportionate contribution of cardiac fibroblasts. Under normal conditions,
cardiac fibroblasts secrete the major components of the extracelluar matrix (ECM), such as
collagen, elastin, fibronectin, vitronectin, laminin and proteoglycan which together contribute
to the microenvironment favorable to cardiomyocytes. However, in the setting of pressure
overload, enhanced angiotensin II signaling by mechanical stretch increases the production of
TGFβ-1 in cardiac fibroblasts which contributes to the cardiac remodeling [12]. TGFβ-1 can
upregulate the function of fibroblasts through autocrine signaling which leads to enlarged
fibroblast population and increased deposition of ECM components [12]. TGFβ-1 can also
upregulate the expression of cardiomyocyte β-adrenergic receptors through paracrine signaling
and result in myocyte hypertrophy [12]. Likewise, TGFβ-1 derived from cardiomyocytes
modulates functions of both myocytes and cardiac fibroblasts [12]. The importance of such
regulation is evident during cardiac hypertrophic remodeling, since dysfunction of cardiac
fibroblasts leads to excessive production of fibrillar collagen [13,14]. In addition, maladaptive
collagen turnover contributes to inappropriate collagen deposition. Collagen turnover is mainly
regulated by matrix metalloproteinases (MMPs) and their inhibitors – tissue inhibitors of
metalloproteinases (TIMPs) in ECM [14]. Studies have emphasized the significance of the
abnormal transition from cardiac fibroblasts to myofibroblasts, the major contributors to
cardiac fibrotic remodeling, in hypertensive cardiac diseases. Myofibroblasts have been shown
to play an important role in arrhymogenic remodeling by (1) generating more fibrotic ECM
which separates muscle bundles, reduces gap junctional coupling between cardiomyocytes
3

and impairs electrical uniform conduction; and (2) forming gap junctional coupling to
cardiomyocytes

which

induces

slow

conduction

and

abnormal

automaticity

[13].

Myofibroblasts also generate extracellular matrix (ECM) with an imbalanced composition of
MMPs and their inhibitors which promotes fibrosis formation [14]. Until recently, cardiac
fibrosis was thought to occur as a secondary response to systemic changes in the renin angiotensin II - aldosterone system (RAAS). It is also thought to be the response to primary
changes in cardiomyocytes by mechanical stretch or local release of growth or inflammatory
factors, such as transforming growth factor β-1 (TGFβ-1), endothelin-1 (ET-1), tissue necrosis
factor-α (TNF-α), etc. [6,14,15]. Two patterns of fibrosis formation have been revealed in
hypertensive hearts: reactive fibrosis and reparative fibrosis [15]. Reactive fibrosis refers to the
initial accumulation of collagen I and III in the pericoronary areas which subsequently extends
to interstitial spaces [15]. The impaired diffusion of oxygen and nutrients, which is caused by
reactive fibrosis, results in cardiomyocyte apoptosis or necrosis, and consequently leads to
reparative fibrosis [15]. Extensive interstitial fibrosis formation leads to increase of ventricular
stiffness, which impairs normal LV diastolic function and results in inadequate filling [16-18].
Over time, the hypertrophic heart progresses to LV failure (congestive heart failure; CHF),
characterized by ventricular dilation, decreased contractile force, pulmonary congestion, and
an increase of cardiomyocyte length-to-width ratio.

Cardiac interstitial fibrosis not only

diminishes LV elasticity and contractility, but also limits oxygen diffusion and increases
oxidative stress which has been recognized as a crucial factor for LV dysfunction [15]. Taking
the advantage of delayed hyper-enhancement magnetic resonance imaging, recent clinical
studies have found a strong correlation between potentially fatal ventricular arrhythmias and
4

myocardial fibrosis in patients with hypertrophic cardiomyopathy [19]. In addition to interstitial
fibrosis, cardiac perivascular fibrosis occurs in the setting of LVH and congestive heart failure,
which impairs the vasodilation function of coronary arteries, causing increased susceptibility to
myocardial hypoperfusion and ischemia [20-25].
Clinical Treatment for LVH Hypertension is the major contributor to LVH, so reducing blood
pressure by diuretic medication (i.e. indapamide, HCTZ) and vascular smooth muscle cell
relaxers (α-blockers, i.e. prazosin, doxazocin) is commonly seen in hypertensive patients. The
RAAS system is considered to be critical in regulating blood pressure. In addition, the RAAS
system can lead to myocyte hypertrophy and cardiac fibrosis in LVH. Thus, the medication
targeting renin (i.e. aliskiren), angiotensin II converting enzyme (i.e. perindopril, enalapril),
aldosterone (i.e. eplerenone) and angiotensin II receptors (i.e. losartan) are also applied in
clinical treatments. Activation of the β1-adrenergic receptors contributes to enhanced myocyte
contraction and increased conduction velocity in the heart. It also increases the renin
production in the kidney. Therefore, β1-blockers (i.e. atenolol) are also common treatments of
LVH. Also, calcium channel blockers (i.e. nifedipine) are used to reduce myocyte contractility in
heart. In practical conditions, inhibitors of RAAS system or β1-blockers are usually combined
with diuretic drugs to be more effective in regression of LVH. Recently, targeting other signaling
pathways (i.e. MAPK pathways, JAK-STAT Pathways, TGFβ signaling, oxidant signaling), which
have been shown important in progression of LVH, has been more extensively explored in
terms of the side effects of the traditional treatments.

5

Perivascular Inflammation Contributes to Cardiac fibrosis LVH is also associated with
inflammatory changes in the peripheral blood and myocardium, which have been proposed to
influence myocardial fibrosis. Inflammatory cells

have been considered indispensable in

hypertension, which is the major trigger of LVH [26]. Inflammatory cells, especially
macrophages, have been shown to accumulate in the organs involved in hypertension, in
particular the kidney [26]. Hypertension was ameliorated in both patients and animal models
with inhibition of T lymphocytes [26]. Other hypertensive triggers, such as neurohomonal
factors, can also enhance the pro-fibrotic effect of the immune system. Studies have shown
that inhibition of inflammatory responses may attenuate cardiac fibrosis [17,18,27-29]. In
DOCA/salt-induced hypertensive rats, pharmacologically targeting monocyte/macrophage
accumulation attenuated cardiac perivascular and interstitial fibrosis and reduced expression of
inflammatory markers, such as interleukin 6 (IL-6) and monocyte chemotactic protein-1 (MCP1) [27,30]. In a rat model of suprarenal aortic constriction, antibody blockade of either
intercellular adhesion molecule - 1 (ICAM-1) or MCP-1 reduced early macrophage recruitment
as well as later myocardial fibrosis [17,28]. Moreover it has been shown that LV remodeling
after myocardial ischemia in rats is attenuated by reducing inflammation-induced cardiac
fibrosis using a P38 mitogen-activated protein kinase (MAPK) inhibitor [31]. However, the
triggers responsible for initiation of perivascular inflammation in the setting of LVH are poorly
understood.

Role of Platelets in Vascular Inflammation Platelets are small anucleated cytoplasmic bodies in
circulation which are generated by megakaryocytes in bone marrow. In settings of vascular
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injury, platelets adhere to the exposed subendothelial matrix via GPIb – vWF and GPVI –
collagen interaction which are substituted later by integrins [32]. Subsequent platelet activation
maintains hemostasis through platelet-platelet interactions (αIIbβ3 – fibrinogen), which
contribute to the primary platelet clot. In addition to their essential role in hemostasis, platelets
are important mediators of vascular inflammation in a variety of settings [33-40]. Activated
platelets express and release granule contents. Stimulated platelets deposit and adhere to
inflamed endothelium through activation-dependent surface expression of adhesive molecules,
such as P-selectin, serving to recruit and interact with leukocytes. Inflammatory mediators
released by platelets, such as IL-8, PF4, RANTEs, TNFα, CD40L, may recruit and modulate
leukocyte responses at sites of vascular inflammation or injury [32,35,37,41-43]. Studies have
also shown that instead of their individual effect, interaction between platelet-derived
cytokines( i.e. platelet factor 4 (PF4) and RANTES) may facilitate leukocyte recruitment and
adhesion to the inflamed endothelium [44]. The same group reported later that blocking the
interaction between PF4 and RANTES reduced the size of atherosclerosis lesion [45].

Due to the complicated platelet function as well as interactions between platelets and
leukocytes, it has been debated for a long time and is still not quite clear whether platelets play
a pro- or anti-inflammatory role in vascular diseases.
Pro: Initially it was believed that platelets promoted inflammation since their activation and
upregulation of platelet-induced cytokines were observed in cardiac hypertrophy and heart
failure [46,47]. Platelets were also activated during myocardial ischemic reperfusion,
contributing to the neutrophil recruitment and myocardial infarction in a P-selectin
7

dependent manner [48]. Platelet-derived P-selectin has been shown to be important for
intimal hyperplasia in a mouse model of carotid artery injury [49]. Using an experimental
arthritis mouse model, Cloutier et al discovered that platelets can enhance vascular
permeability by promoting formation of endothelial gaps, possibly through their serotonin
secretion [50]. Specific inhibition of platelet activation or knockout of platelet serotonin has
been shown to decrease bleomycin-induced tissue fibrosis [51]. Furthermore, platelet
depletion by neuraminidase or inhibition by clopidogrel benefited the mice which were
suffering from acute hemolysis-associated fatal pulmonary arterial hypertension (PAH) [52].
In another animal model of autoimmune encephalomyelitis, platelet depletion by GPIbα
antibody reduced leukocyte recruitment, local inflammation and the CNS lesion [53]. In the
clinical studies, application of anti-thrombotic therapy, such as clopidogrel (P2Y12 receptor
inhibitor), is suggested to decrease the mortality due to heart failure or acute myocardial
infarction [54,55]. Cilostazol is a phosphodiesterase 3 (PDE3) inhibitor and inhibits platelet
aggregation by upregulating cAMP-mediated PKA activation. Serving as an alternative antiplatelet therapy, application of cilostazol has been shown to decrease the restenosis after
percutaneous transluminal coronary angioplasty (PTCA) [56]. A cohort study also showed
that anti-platelet therapy could reduce the probability of acute lung injury (ALI) [57].

Anti: Denisa Wagner’s group has recently shown that in inflammatory diseases, including
tumors, platelets and their secretion are critical for maintenance of vascular integrity, loss
of which tends to cause severe hemorrhage [58,59]. The benefits of platelet gel for
endogenous myocardial repair and preserved cardiac function in a myocardial infarction
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model have also been reported by Cheng et al [60]. In terms of more complicated roles of
platelets in different settings of vascular inflammation, anti – platelet therapy should be
carefully applied with consideration of the potential adverse effects on cardiac function and
more efforts should be put to elucidate the underlying mechanisms of the role of platelets
in cardiac diseases.

Platelet Function in Hypertensive Cardiac Diseases Forty-five years ago, scientists first
discovered that platelet adhesion to vessel wall was dramatically increased in hypertensive
cardiac diseases [61]. Indices of Platelet activation, such as mean platelet volume (MPV),
platelet mass, P-selectin per platelet (pP-sel), soluble P-selectin (sP-sel), lower platelet
granularity, are upregulated in hypertensive patients [62]. Even for prehypertension patients,
mean platelet volume (MPV), an indicator of platelet activation, is significantly increased
[63,64]. Mechanisms of pathological platelet activation in hypertensive diseases include (1)
upregulation in sympathetic nerve system (SNS) and renin-angiotensin-aldosterone system
(RAAS) activity which contribute to enhanced platelet aggregation; (2) damaged or inflamed
endothelium and therefore decreased nitric oxide (NO) which promotes platelet adhesion and
aggregation; (3) decreased platelet-derived NO which causes increase in circulating levels of
monocyte-platelet aggregates (MPAs); (4) increased shear stress which triggers platelet
secretion and activation [65]. Interestingly, reducing blood pressure by anti-hypertensive
medication – quinapril ( angiotensin-converting enzyme (ACE) inhibitor) and/or nifedipine (
calcium-channel blockers) could significantly inhibit platelet hyperactivity [66]. Furthermore,
combination of angiotensin II receptor antagonist (losartan) and anti-dyslipidemia medication
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(simvastatin) reduced platelet activation in patients with hypertension, hyperlipidemia and
diabetes [67]. Recently, anti-platelet therapies, such as aspirin, clopidogrel and cilostazol, have
been shown to reduce the risk of cardiovascular events and improve the outcome of patients
with hypertension [65] [68].

Lymphocyte Function in Cardiovascular Diseases As inflammatory cells, lymphocytes have
been shown to be involved in cardiovascular diseases in animal models. In mice with carotid
collar injury, intimal hyperplasia is positively correlated with increased number of CD1drestricted natural killer T lymphocytes in spleen and peri-carotid adventitia [69]. T lymphocytes
also regulate cardiac diastolic function and contribute to hypertension-related cardiac ECM
fibrotic remodeling by regulating collagen production and MMPs activity [70,71]. On the other
hand, different lymphocyte subsets and lymphocyte signaling might play a protective role in
cardiac pathological development [72-77]. For instance, injection of CD4+CD25+ regulatory T
cells (Tregs) attenuated Angiotensin II-induced cardiac hypertrophic and fibrotic responses, and
maintained the normal distribution of gap junctions [74]. Furthermore, adoptive transfer of B
cells to Rag1-/- mice decreased intimal hyperplasia in carotid artery in response to
periadventitial cuff injury [78]. Furthermore, lymphocyte antigens (DR3 and DR4) are detected
in patients suffering from systemic sclerosis and rheumatoid arthritis coexistent with cardiac
hypertrophy [79,80].

T Lymphocytes in Hypertension Lymphocytes, especially T cells, are important in regulating
blood pressure and contributing to hypertensive cardiac remodeling. David Harrison’s group
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reported in 2007 that angiotensin II and DOCA-salt-induced hypertension were significantly
attenuated in Rag1-/- mice which are deficient of T and B lymphocytes. Interestingly, T
lymphocyte transfer completely restored the hypertension and vascular dysfunction which was
hypothesized to be mediated by TNF-α [81]. Apart from responding to exogenous Angiotensin
II, T lymphocytes can produce Angiotensin II endogenously which modulates their function in
hypertension [82]. Central nervous system (CNS) has also been shown to independently
influence Angiotensin II-induced hypertension and T lymphocyte activation [83]. The
contribution of lymphocytes to Angiotensin II-induced hypertension was confirmed by another
group using a SCID mouse model [84].
Platelet-Lymphocyte Interaction in Vascular Inflammation Activated platelets stick to the
vascular wall to facilitate lymphocyte tethering, rolling and adhering to inflamed endothelium
or exposed subendothelial matrix. This is first initiated mainly through P-selectin (platelet) –
PSGL-1 (lymphocyte) interaction and is substituted by integrins for later firm adhesion [85].
Platelet-lymphocyte conjunction through P-selectin – PSGL-1 interaction will also promote
lymphocyte recruitment to sites of vascular inflammation in animal models [86,87]. Secreted or
surface-expressed cytokines from platelets, such as platelet factor 4 (PF4) and CD154, have
been shown to regulate T lymphocyte function [85]. Using a CD40 ligand (CD40L) deficient
mouse model, platelet-derived CD40Ls have been shown to play an important role in
production and maturation of IgG in B lymphocytes [85,88,89]. Another study suggested that
CD40Ls on platelet-derived micro vesicles (PDMVs) might be the biologically active form [88].
Platelet-derived CD40Ls are also shown to mediate transfusion-induced inflammatory
responses, such as [90]. On the other hand, lymphocytes influence platelet function through
11

direct interaction or secreted contents. Platelet deposition observed in ischemia/reperfusion
was significantly reduced in mice deficient of T cells and was recovered in mice reconstituted
with WT splenocytes [91]. T cell-derived CD40L contributes to platelet activation thereby
causing platelets to secrete RANTES which further aids in T-cell recruitment and activation [92].
In addition, T cells can regulate platelet cytotoxicity through antibodies (IgE and IgG) or
cytokines (IFN-γ, TNF-α) [85].

Transverse Aortic Constriction (TAC) is an established model to study pressure-overloadinduced cardiac remodeling, in which a constriction of the lumen is formed by suture of the
aortic arch between the right and left carotid arteries (Figure 10). TAC creates a pressuredifference across the constricted jet, which mimics the similar effect caused by hypertension or
aortic stenosis in patients. It has been suggested that after TAC the LV function is impaired
abruptly (within 1 day), but gradually returns to a normal level (around day 10) which will last
for a while before the onset of decompensation and heart failure [93]. TAC induces LV
remodeling, including myocardial hypertrophy and fibrosis. Studies also show that TAC-induced
LV remodeling could be reversed by removing the constriction 2 weeks after TAC [94]. Our data
corroborates that of the Hartley group which suggests a reduction of coronary flow reserve
(CFR) following TAC [95-97], indicating coronary artery dysfunction. We previously reported
that pressure overload in mice created by TAC is associated with a marked perivascular
inflammation, reactive myocardial fibrosis, and medial thickening of intramyocardial coronary
arteries [98]. Xia et al also characterized the inflammatory responses in TAC model and
detected the increased proinflammatory cytokines and inflammatory cell myocardial infiltration
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[99]. Together this evidence suggests that acute perivascular inflammation plays a role in
remodeling of intramyocardial arteries during LVH.
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SECTION 2: Platelet Granule Secretion

Exocytosis (secretion) by inflammatory cells is one of the major routes whereby cytokines or
molecules are released or expressed on the outer surfaces to maintain cell function during
vascular physiological or pathological events. Three different patterns of exocytosis have been
identified, including 1) classical exocytosis: single granule forming, fusing with membrane and
releasing cargo; 2) compound exocytosis: multiple granules integrating into one secretory
vesicle before secretion 3) piecemeal degranulation (PMD): partial loss of secretory contents in
the focal area of granules, a common observation in mast cells, eosinophils and basophils [100].
Most of the inflammatory cells bear classical and compound secretory patterns (macrophages
only have the classical one). PMD secretion is often observed in mast cells, eosinophils and
basophils.
In general, the secretion process includes vesicle transport, tethering, docking, priming and
fusing to the plasma membrane of the secreted sites. Insertion of newly synthesized plasma
membrane proteins and secretion of extracellular matrix components are fulfilled through the
constitutive exocytosis pathway; while release of other granule contents or membrane
proteins, which require a specific signal trigger is through strictly regulated exocytosis [101].
Recent breakthroughs in characterization of the platelet secretory machinery suggest that
platelets play a critical role in vascular inflammation.
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Platelet Granule Components and Development platelets contain three types of granules: αgranules, dense granules and lysosomes. These granules have distinct morphology, contents,
and respond differently to secretory stimuli.

α-Granules are the largest granules (diameter: 200 nm) and are present within a range of
50-80 per platelet [102]. Platelet α-granules are budded from the trans-Golgi compartment
of megakaryocytes [103] and contain a variety of coagulation factors (i.e.. factor V, XI),
growth factors (i.e. TGFβ-1, PDGF), angiogenic factors (i.e. VEGF, PF4), membrane-born
proteins (i.e. P-selectin, GPIb, αIIbβ3), cytokines and chemokines (IL-1β, RANTES, IL-8), and
adhesion molecules (i.e. fibrinogen, vWF) (Table 144-2) [102]. The above-mentioned
proteins can also be categorized into (1) platelet-specific proteins, such as PF4 and βthromboglobulin family, which are derived only from megakaryocytes; (2) platelet-selective
molecules, such as thrombospondin, P-selectin and vWF, which are highly concentrated in
platelet compared to blood; (3) proteins taken up by platelets though endocytosis, such as
fibrinogen [103]. Inside the α-granules, there are 4 morphologic zones: granular peripheral
membrane, tubular and vesicular part, electron-lucent area and electron-dense nucleoid;
each of which contains different types of molecules [103]. Some of the α-granules have the
ultrastructure of exosomes, which are characterized by smaller size (40-100 nm) and
expression of CD63 and can be secreted upon thrombin stimulation [104].
While the underlying mechanisms of α-granule deficiency have not been fully elucidated,
such deficiencies have been readily observed in patients with gray platelet syndrome,
Medich giant platelet disorder and White platelet syndrome [105]. In a mouse model, α-
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granule defect or decrease in granule population appears under the following conditions:
(1) absence of certain transcription factors (eg. GATA, Hzf); (2) mutation of proteins
involved in vesicular trafficking (eg. VPS33B, Rab geranylgeranyl transferase, Rab27b); (3)
absence of membrane composition (eg. ABCG5) [105]. Recently, mutation of NBEAL2, the
gene encoding the neurobeachin-like 2 (NBEAL2) protein which is important in vesicular
trafficking and α-granule biogenesis, was identified as another cause of gray platelet
syndrome [106-108].

Dense Granules are much smaller (20-30 nm) than α-granules and are present in the range
of 3 to 8 granules per platelet. Dense granules have a high concentration of calcium and
phosphate which contributes to their electric density [97]. Dense granules maintain a high
level of serotonin which is taken up from plasma and is trapped there due to the granule
acidic pH (6.1) [109]. Dense granules also contain a high concentration of ADP/ATP and
magnesium which, in addition to calcium and serotonin, creates high osmotic pressure and
makes the granule opaque-looking under transmission electron microscopy [102,103].
Dense granules contain some lysosome membrane protein, such as CD63 and LAMP-2, but
not LAMP-1.
Dense Granule Deficiency was observed in patients suffering from Hermansky-Pudlak
syndrome (HPS) which is an autosomal recessive disease associated with pigmentation
disorders and is caused by mutations of different HPS gene isoforms [103]. Due to the
defects of platelet dense granules, those patients have bleeding disorders and they may
also have abnormality in the lung, liver, intestine and heart. Defects of homologues of HPS
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proteins cause a similar phenotype in mice (Table 1) [103]. Mutations of other genes, such
as gene encoding Rab27a, a regulatory protein important in vesicular trafficking, also cause
dense granule defects [103].
Lysosomes: Platelet lysosomes maintain the size of 175-250 nm and have the subtypes of
primary and secondary lysosomes [103]. Lysosomes are derived from the endosome and
contain membrane proteins CD63, LAMP-1 and LAMP-2. The stimuli required to induce
lysosomal secretion in vitro has been indicated to be much stronger than the stimuli
required to induce secretion of α- and dense granules. Therefore, lysosome exocytosis may
represent a high level of platelet activation [102]. Platelet lysosomes contain numerous acid
hydrolases, such as elastase and collagenase, which might be involved in vascular
disintegrity during thrombosis [110].

Table 114–2. Platelet Granule and Cytoplasmic Contents
Dense granules I1574

ADP 653 mM
ATP 436 mM
Calcium 2181 mM
Serotonin 65 mM
Pyrophosphate 326 mM
GDP
Magnesium
Granules120,129,132
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To Be Continued

Platelet-specific proteins:
Platelet factor 4 (PF4)
-Thromboglobulin ( -TG) family (platelet basic protein, low-affinity PF4,
-thromboglobulin-F)

-thromboglobulin, and

Multimerin
Adhesive glycoproteins:
Fibrinogen
von Willebrand factor (VWF)
VWF propeptide
Fibronectin
Thrombospondin-1
Vitronectin
Coagulation factors:
Factor V
Protein S
Factor XI
Mitogenic factors:
Platelet-derived growth factor (PDGF)
Transforming growth factor-

(TGF- )

Endothelial cell growth factor
Epidermal growth factor (EGF)
Insulin-like growth factor I
Angiogenic factors:
Multiple inducers and inhibitors (see text)
Fibrinolytic inhibitors:
2-Plasmin

inhibitor (

2-PI)
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To Be Continued

Plasminogen activator inhibitor-1 (PAI-1)
Albumin
Immunoglobulins
Granule membrane-specific proteins:
P-selectin (CD62P)
CD63 (LAMP-3)
GMP 33
Other secreted or released proteins120,132

Protease nexin I
Gas6
Amyloid

-protein precursor (protease nexin II)

Tissue factor pathway inhibitor (TFPI)
Factor XIII
1-Protease

inhibitor

Cl-inhibitor
High-molecular-weight kininogen
2-Macroglobulin

Vascular permeability factor (VPF) / Vascular endothelial growth factor A (VEGF-A)
Interleukin (IL)-1
Histidine-rich glycoprotein
Chemokines:
MIP-I

(CCL3)

RANTES (CCL5)
MCP-3 (CCL7)

To Be Continued
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GRO

(CXCL1)

PF4 (CXCL4)
ENA-78 (CXCL5)
NAP-2 (CXCL7)
IL-8 (CXCL8)
TARC (CCL17)

Smyth SS, Whiteheart SW, Italiano JE, Coller BS (2010) Platelet Morphology, Biochemistry and
Function. Williams Hematology. 8e ed.

King SM, Reed GL (2002) Development of Platelet Secretory Granules. Semin Cell Dev Biol
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The Key Step of Platelet Secretion: Membrane Fusion
Significance and Involvement of Lipid Components Membrane fusion is a highly regulated
process in which fusion between lipid bilayers of vesicle and the targeted membrane occurs
when energy demand is met. About 70% of platelet membrane lipid components are
phospholipids [111]. Until now, it has been shown that at least two types of lipids are essential
for platelet secretion.

Phosphatidic Acid (PA) While the significance of PA in membrane fusion is not clear, its
involvement has been corroborated by numerous studies. Manipulating PA production in
permeabilized platelets through activation of PKC and in the presence of GTPγ-s can
potentially increase platelet granule secretion [112]. Also, addition of PA can enhance PKC
or GTPγ-s-mediated platelet dense granule secretion [113]. In other systems, such as
chromaffin and PC12 cells, inhibition of PA production reduced membrane fusion and
granular release [114]. Also the same group found that exogenously adding LPC could
restore the exocytosis in those cells, indicating that PA might contribute to the membrane
fusion through affecting membrane curvature [114]. PA might also enhance the
environment for protein-protein interactions and cell signaling thereby further contributing
to membrane fusion [115].
Phosphatidylinositol 4, 5-Bisphosphate (PIP2) Similar to PA, PIP2 is very important in
granule secretion [116]. The cleavage of PIP2 by addition of phosphatidylinositol-specific
phospholipase C decreased Ca2+- induced platelet α-granule secretion in a dose- and timedependent manner [116]. Antibodies to type II phosphatidylinositol-phosphate kinase
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reduced PIP2 levels and subsequently resulted in inhibition of α-granule secretion [116]. The
mechanisms through which PIP2 affects the secretion are not well understood. It has been
indicated that PIP2 interacts with secretion complex components and their regulators.
Increase of PIP2 level in the plasma membrane inhibited SNARE-dependent liposome fusion
[117]. However, PIP2-binding-activated protein CAPS significantly increases SNAREdependent liposome fusion in the presence of PIP2, indicating that PIP2 plays a regulatory
role, rather than an inhibitory role, in SNARE-dependent membrane fusion [117]. Recently,
another study showed that PIP2 can also regulate Munc13-4-dependent granule secretion in
human natural killer (NK) cells [118]. Granule secretion, which triggers Munc13-4
membrane raft recruitment and subsequent internalization, is inhibited by RNA-silencing of
PIP5K; and AP-2-dependent Munc13-4 internalization is also blocked [118].
Soluble NSF Attachment Protein Receptor (SNARE) Complexes are membrane proteins which
have been considered essential for secretory vesicle docking and fusion. Replacement of one of
the three glutamines with arginine in the highly conservative core of SNARE causes lethal
effects or growth defects in yeast which can be compensated by replacement of the other
arginine with glutamine in the core area [119]. Similarly genetic defects of SNAREs in other
species, such as Drosophila, C. elegans and mice also cause neurotransmission dysfunction
[101]. SNAREs were formerly divided into two categories: vesicular SNARE proteins (v-SNARES),
such as VAMP proteins, and targeted membrane SNARE proteins (t-SNARES), such as syntaxin
and SNAP-23. It is currently believed that v- and t-SNAREs are not solely located on vesicular or
targeted membranes. One SNARE complex is generally composed by one VAMP helix, one
Syntaxin helix and two helices of SNAP-23 protein. Different cell types or granules possess
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different isoforms of VAMP, Syntaxin and SNAP [100]. In 1999, Flaumenhaft et al first observed
a core complex in human platelets (consisting of VAMP protein, SNAP-23 and syntaxin 4) which
was shown to be crucial for platelet exocytosis [120]. Lemons et al confirmed the core complex
in platelet α-granule secretion, further indicating that both syntaxin 2 and 4 are involved [121].
Permeabilized platelets treated with anti-syntaxin 4 antibodies or tetanus toxin (which cleaves
VAMP-1,-2 and -3) had significantly less granule secretion upon stimulation, indicated by Pselectin membrane expression [120]. SNAREs were also shown to communicate with the
platelet actin cytoskeleton during platelet α-granule secretion [122]. The most recent data
have identified four Vesicle Associated Membrane Proteins (VAMP) isoforms in human
platelets: VAMP-2[120], VAMP-3 [123], VAMP-7 [124] and VAMP-8 [125], out of which VAMP-3
and VAMP-8 were initially thought to be required for secretion of platelet α-granules and dense
core granules [120,125]. However, studies on VAMP-3 null mouse platelets suggest that VAMP3 is not necessary for normal platelet granular release [126]. Further, platelet secretions are
defective in VAMP-8 deficient mice, indicating that VAMP-8 is the major v-SNARE in platelets
[124]. Immuno-blocking of SNAP-23, a t-SNARE in the secretory core complex, inhibits αgranule, dense core granule and lysosome secretion in permeabilized platelet [121,127,128].
This was further confirmed by another group, using an dominant negative SNAP-23 mutant,
showing that competitive binding of the mutant to the docking site suppresses the native
protein binding and subsequently inhibits platelet granule secretion [129]. In the presence of
Ca2+, SNAP-23 is degraded by calpain cleavage in a dose- and time-dependent manner after
platelet degranulation, suggesting its role in membrane exteriorization [130,131].

It was

considered that Syntaxin 2 and 4 were critical for platelet granule secretion by antibody
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blocking studies [121,127,128]. Compared to VAMP and SNAP-23, syntaxin 2 and 4 are more
equally distributed in all the membranes [116]. However, recently Ye S. et al from Whiteheart’s
lab found that syntaxin 11, rather than syntaxin 2 or 4, is the critical t-SNARE for platelet
exocytosis and the previous finding about syntaxin 2 and 4 are due to the cross-reactivity of the
antibody [132]. In the resting status, two SNAP-23 helices and one Syntaxin helix form the cisSNARE complex located on plasma membrane. Upon activation, the cis SNARE complex is
transformed to the four-helix trans SNARE complex through binding to one VAMP helix on the
vesicle membrane. The structure transition from cis SNARE to trans SNARE leads to fusion
between vesicle membrane and plasma membrane and the release of granular contents.
Chaperone Proteins many chaperone proteins interact with the secretory core complex to
regulate the granule release. Binding of α-SNAP to NSF, a hexameric ATPase, activates the
latter which will transform the cis SNARE to the trans SNARE, facilitating the fusion between the
opposed membranes. Inhibition of NSF by recombinant peptides significantly reduced platelet
α- and dense core granule secretion in a dose-dependent manner [133]. There are three
isotypes of Munc-18 proteins (Munc-18 a, b and c) which interact and sequester different
syntaxin proteins in platelets. Phosphorylation of Munc-18 c by protein kinase C (PKC) will
decrease the binding affinity of Munc-18 c to syntaxin which also facilitates the SNARE
transformation from cis to trans, and therefore allows granule release [115]. The role of
Munc18-b in platelet secretion is also identified recently by forming complex between syntaxin11, SNAP-23, and VAMP-8 [134]. Rab proteins are the largest family within the Ras GTPase
superfamily and are considered important in vesicle tethering before membrane fusion [135].
Individual Rab GTPase is located at certain cellular compartment and regulates
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distinct

trafficking steps when activated by GTP loading. Rab1a and 1b, 3b, 4, 6c, 8, 11, 27a and b, 31,
38 have all identified and characterized in platelets [136-139]. Rab27a mutation has been
associated with Hermansky-Pudlak and Griscelli syndrome in human and it also causes murine
(ashen mice) granular secretion defects in a variety of secretory cells , such as melanocytes,
cytotoxic T lymphocytes, and platelets [140-147]. The effect of Rab27a mutation on platelet
function has been debated. It was found by Wilson et al that ashen mice had a significantly
longer bleeding time due to their dense granule number and content defects [146]. On the
contrary, Seabra’s group showed that ashen mice possess normal platelet morphology and
function normally in response to high dose of agonists, and Rab27a deficiency could be
compensated by Rab27b [115]. The differences in the findings of the above groups are
potentially due to differing mouse genetic backgrounds and assay set-up [145]. The function of
Rab27b in platelets has also been elucidated by Seabra’s group suggesting that mice with
Rab27b mutation have attenuated dense granule release and platelet aggregation which was
not further dampened by Rab27a mutation [148].
Munc13-4 Dependent Granule Secretion and Jinx Mice Munc13-4 protein was first cloned and
identified in rat lung and spleen tissue by Koch H. et al in 2000 [149]. It was later observed that
Munc13-4 RNA was also expressed in human hematopoietic cells [150]. Munc13-4 belongs to
Munc13 protein family in which Munc13-1, Munc13-2 and Munc13-3 isoforms are recognized
as important regulators of synaptic exocytosis, specifically in the central nervous system (CNS)
[151,152]. Encoded by Unc13d gene, Munc13-4 functions similarly to its homologues in CNS
and is important for secretory vesicle priming and fusion in hematopoietic cells, including
platelets, natural killer (NK) cells, cytotoxic T lymphocytes, neutrophils and mast cells [150,15325

158]. Munc13-4 regulates granule secretion by binding to Rab27 (Rab27a and Rab27b), the
chaperone proteins responsible for tethering vesicles to the targeted membrane before
membrane fusion [158,159]. Munc13-homology domains (MHDs) are present in all Munc13-like
proteins and are required for proper Munc13-4 membrane location [149]. Studies have shown
that platelet Munc13-4 proteins are present in the cytosol and on the plasma membrane, but
not in dense core granules; whereas Rab27 proteins are exclusively present on the plasma
membrane fraction, a large proportion of which are located on dense core granule [159]. In
cytotoxic T lymphocytes and NK cells, Munc13-4 colocalizes and directly interacts with Rab27
and is indispensable in the interaction between Rab27a and Rab11 to fulfill the endosomal
assembly [160]. Mutation of MUNC13-4 gene is closely associated with a fatal human disease –
familial haemophagocytic lymphohistiocytosis type 3 (FHL3) [150,161]. FHL3 patients suffer
from aberrant granule secretion of cytotoxic T cells, which leads to the abnormal enlargement
of liver and spleen, anemia and thrombocytopenia. Unc13dJinx (Jinx) mice are the animal model
of FHL3 [162]. Jinx mice have a point mutation in Unc13d gene (mouse orthologue of MUNC134) which causes a splicing defect, generating truncated Munc13-4 protein which will undergo
ubiquitination leading to its subsequent degradation [162]. Interestingly, Jinx mice under
normal condition do not exhibit FHL3 characteristics. It is only when they are infected with
lymphocytic choriomeningitis virus that they exhibit FHL3-like phenotype [162]. Absence of
Munc13-4 in platelets of Jinx mice leads to severely compromised secretion of dense core
granules, α-granules and lysosomes which could be recovered by adding normal Munc13-4 to
permeabilized platelets [154]. Because the amount of Munc13-4 in platelets is much lower than
other secretory regulators, it is suggested that Munc13-4 is a limiting factor in platelet granular
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secretion [154]. The data from heterozygous mice further confirmed that platelet granule
secretion is correlated with Munc13-4 level and can be recovered by titration of the
recombinant human Munc13-4 [154]. Because of granular secretion defects, Jinx mice have
increased bleeding time.

Potential Mediators from Platelets in Cardiac Hypertrophic Remodeling
Serotonin (5-hydroxytryptamine, 5-HT) has been recognized for many years as an important
neurotransmitter modulating brain function through universally-expressed serotonin receptor
subtypes (16 identified receptors until now) in the CNS and influencing all of the human
behavioral activities [163]. Defects in serotonin signaling are related to neurological and
cognitive disorders [163,164]. The signaling of different serotonin receptors can regulate one
behavior in an integrated pattern and one serotonin receptor may also be involved in different
behavioral events [163]. For example, 5-HT1A and 5-HT2C cooperate to regulate the behavior of
anxiety, but 5-HT2C is also involved in regulating locomotion and appetite [163]. Despite the
undeniable importance of serotonin in the CNS, 95% of serotonin is actually stored in the
peripheral vascular system, mainly in the platelet dense granules. The serotonin found within
platelets is synthesized and released by the enterochromaffin cells in the intestinal wall and is
taken up by platelets through 5-HT transporter (SERT) [165]. Taking the advantage of
established serotonin receptor knockout animal models and serotonin receptor antagonists,
studies have further revealed its influences in pulmonary, gastrointestinal (GI), and
cardiovascular systems [163]. Series of studies have shown that serotonin regulates platelet
function, vascular tone, heart rate, cardiac development and remodeling [163]. Serotonin has
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also been shown to be involved in liver regeneration [166]. 5-HT2B receptor has been shown to
be indispensable in embryonic cardiac development since the disruption of 5-HT2B gene in mice
causes embryonic or neonatal death [167]. This study also indicated that cardiac development
is regulated through activation of ErbB-2, a tyrosine kinase receptor [167]. Later, the same
group observed prominent cardiac hypertrophic responses in transgenic mice overexpressing
Gq-coupled 5-HT2B receptor, indicating a role for serotonin in cardiac hypertrophy mediated by
PLC activity [168]. Upregulation of 5-HT2B was observed in norepinephrine (NE)-induced and
aortic constriction-induced cardiac hypertrophy [169,170]. Furthermore, cardiac hypertrophy
induced by isoproterenol perfusion could be attenuated by application of 5-HT2B receptor
antagonist SB206553 or in 5-HT2B -/- mice probably through inhibiting secretion of IL-6, IL-1β and
TNF-α from ventricular fibroblasts [171]. It was also been confirmed that blocking 5-HT2B
receptor by SB215505 reduced the superoxide generation and NAD(P)H oxidase activity in both
cardiomyocytes and cardiac fibroblasts during hypertrophic cardiac remodeling [172]. These
studies suggested a critical role of serotonin in both physiological and pathological
development of the heart with an emphasis on 5-HT2B receptor signaling. However, an in vitro
study showed that addition of 5-HT2B antagonist SB206553 only partially inhibited serotonintriggered hypertrophy of cultured rat ventricular myocytes, while inhibition of serotonin turnover by monoamine oxidase-A (MAO-A) inhibitor, pargyline, significantly blocked hypertrophic
responses mainly through reducing production of the reactive oxygen species (ROS) [173]. The
partial inhibition by 5-HT2B antagonist was confirmed by another in vivo study in which
SB204741 partially attenuated the NE-overload-induced cardiac hypertrophy and cardiac
apoptosis in rats [169]. The significance of MAO-A has been further identified in MAO-A
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knockout mice in which peripheral serotonin as well as ventricular expression of 5-HT2A
receptor are significantly increased [174]. Independent pathways have also been elucidated
through which 5-HT2A and MAO-A contribute to serotonin-induced cardiac hypertrophy [93].
The above evidence contributed to the development of drugs designed to modulate serotonin
or its receptor (i.e. ketanserin) in order to treat hypertrophic cardiomyopathy. Such novel
drugs, however, are not without side effects which include QT interval prolongation and
increased risk of sudden cardiac death [175].
Transforming Growth Factor β-1 (TGFβ-1) TGFβ-1 is secreted by many cell types in a latentform sequestered by TGFβ-1 latency-associated peptide (LAP). It will be subsequently activated
by stimuli such as acidic microenvironment, MMPs, shear stress and thrombospondin-1 (THP-1)
which can facilitate release of LAP. TGFβ-1 signals by binding to TGFβ type II receptor and
subsequently recruiting and activating the TGFβ type I receptor, which will activate its
downstream effectors, such as Smad proteins. In the canonical pathway, TGFβ type I receptor
phosphorylates and activates Smad 2/3, leading to the formation of Smad 2/3/4 complex which
will translocate to the nuclei, bind to the promoter region of certain genes and regulate gene
expression. Smad 6/7 inhibits Smad 2/3 phosphorylation by binding to TGFβ type I receptor or
recruiting Smad ubiquitination-related factor 1 and 2 (Smurf 1 and 2) [176]. Alternatively, TGFβ
type I receptor activates other targets, such as TGFβ-activated kinase 1 (TAK1), which will
activate P38 through MKK6 and MKK3, thereby upregulating gene expression of extracellular
matrix components, such as collagen [176,177]. The non-canonical pathway is more closely
associated with pathological remodeling [176]. It has been universally recognized that TGFβ-1
contributes to cardiac hypertrophic and fibrotic remodeling [176,178]. TGFβ-1 can be induced
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by cardiac injury and hypertrophic stimuli, such as Angiotensin II and pressure overload
[177,179,180]. TGFβ-1 levels are is also enhanced in myocardial hypertrophy and heart failure
[176]. Both cardiomyocytes and cardiac fibroblasts produce TGFβ-1 which can modulate the
function of cardiac cells through autocrine or paracrine pathways. A recent report showed that
circulating platelets maintain an abundant storage of TGFβ-1 and contribute to plasma TGFβ-1
levels [179]. Depletion of platelet TGFβ-1 will partially protect the heart from pressureoverload-induced remodeling and dysfunction [179]. TGFβ-1 is important for mice embryonic
hematopoiesis and vasculogenesis, since the TGFβ-1-null phenotype contributes to yolk sac
defect which often leads to embryonic death [181]. Forty percent of TGFβ-1 null mice that were
born alive rapidly developed multi-organ inflammatory diseases two weeks later and died by
two to three weeks after birth [182]. An immuno-deficient mouse

in which TGFβ-1 is

genetically knocked out, was able to abolish angiotensin II-induced cardiac hypertrophy with no
impact on cardiac fibrosis formation [180], while transgenic mice overexpressing TGFβ-1
showed cardiac hypertrophy and increased myocyte contractility [183]. The effect of disrupting
TGFβ-1 signaling on cardiac function is still debatable. It was observed that intraperitonial
injection of a monoclonal antibody to neutralize TGFβ-1 (NAb) in rodents did not alter myocyte
hypertrophy but prevented aortic-constriction-induced perivascular and myocardial fibrosis
[177,184]. However, data are not consistent on whether Nabs could protect the animals from
diastolic dysfunction [177,184].

Interestingly, competitive blocking of TGFβ-1 signal by

expressing a dominant-negative mutant of TGFβ type II receptor in mice led to left ventricular
dilation and dysfunction without affecting cardiac hypertrophy and interstitial fibrosis [185],
while myocyte specific knockout of TGFβ type II receptor in mice attenuated cardiac
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hypertrophy and dysfunction [177]. The differences are probably due to activation of distinct
downstream pathways in different target cells. It has been shown that exacerbation of cardiac
hypertrophy remodeling by NAbs is mainly due to disruption of Smad3 signaling without
affecting TAK1 activation in noncardiomyocytes, and inhibition of both Smad3 and TAK1
pathways in cardiomyocytes preserved cardiac function and reduced cardiac hypertrophy [177].
Sphingosine 1-Phosphate (S1P), generated from sphingosine phosphorylation by sphingosine
kinases, is a potent lipid ligand which can regulate cell growth, migration, contractility and
intracellular calcium mobilization through binding to its receptors. The majority of S1P comes
from platelets, erythrocytes and vascular endothelium. In the circulation, albumin and HDL are
the major carriers of S1P. S1P receptors are G protein coupled receptors (GPCR) and to date
five of them have been identified: S1P1, S1P2, S1P3, S1P4 and S1P5, which are organ and cellspecifically distributed. S1P1, S1P2, S1P3 are present in the heart with S1P1 being the
predominant S1P receptor in cardiomyocytes. The effects of S1P on the heart mainly depend
on the receptor subtype it binds to and the coupled G protein signaling. S1P1 mainly couples to
Gi/o. Upon activation, Gi/o releases the Gα subunit which can inhibit adenylate cyclase and
reduce intracellular cAMP, decreasing the myocyte contractility. Gβγ can also induce
downstream signaling. S1P2 and S1P3 are coupled to Gi/o, Gq and G12/13 [186]. The role of S1P on
cardiac hypertrophy has been debated. Studies on cardiac remodeling in settings of myocardial
hypoxia and ischemia reperfusion revealed the protective role of S1P through activating Akt
pathway, which will inhibit GSK3 and activate NOS [187]. The cardiac protective role of S1P is
probably mediated through S1P2 and S1P3 receptors because S1P-induced cardiac protection
was missing in S1P2 or S1P3 knockout mice and was even more significant in S1P2/ S1P3 double
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knockout mice [188]. However, it has also been shown in an in vitro experiment that S1P
triggered hypertrophic responses in rat neonatal myocytes in a dose-dependent manner [189].
S1P1 receptor probably mediated it since specific anti-S1P1 antibody inhibited the hypertrophy
[189]. In an in vivo experiment, intraperitoneal injection of S1P for 4 weeks induced cardiac
hypertrophic responses which were shown by increased HW: BW, cardiomyocyte size and ANP
protein level [190]. It has been revealed that Gi/o signaling through S1P1 is involved cardiac
hypertrophic responses. However, Gq-mediated PLC activation also induces cardiac hypertrophy
which suggests a role of S1P3 [187].
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Section 3: Summary

Although inflammation has been observed in settings of pressure overload and antiinflammatory procedures are associated with a better cardiac outcome, the detailed features of
early perivascular inflammation, for example, the involved inflammatory cell types and their
temporal distribution, have not been fully characterized. Moreover, the individual effects of
those inflammatory cells on LV and coronary remodeling and the underlying mechanisms are
also not clear. Therefore, my study, which will be presented in the next two chapters, is focused
on characterizing the early perivascular inflammation in TAC-induced LV pressure overload and
the contribution of individual inflammatory cell type (CHAPTER 2) and inflammatory secretion,
granular secretion of platelets in particular, to cardiac remodeling (CHAPTER 3).

Copyright © Fanmuyi Yang 2012
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CHAPTER 2: CORONARY ARTERY REMODELING IN A MODEL OF LEFT VENTRICULAR PRESSURE
OVERLOAD IS INFLUENCED BY PLATELETS AND INFLAMMATORY CELLS

INTRODUCTION
Left ventricular hypertrophy (LVH) is a common risk factor for the development of heart failure
and an independent predictor of cardiovascular death. LVH usually develops in the setting of
mechanical stress, overactive sympathetic drive, or as a consequence of genetic abnormalities.
One important pathophysiologic characteristic of hypertensive LV remodeling is the production
of excessive interstitial fibrillar collagen by fibroblasts [13]. Extensive fibrosis is thought to
impair normal LV diastolic function and oxygen diffusion, leading to LV dysfunction [15]. Recent
clinical studies have found a strong correlation between potentially fatal ventricular
arrhythmias and myocardial fibrosis, as detected by delayed hyper-enhancement magnetic
resonance imaging in patients with hypertrophic cardiomyopathy [19]. In addition to interstitial
fibrosis, perivascular fibrosis occurs in the setting of LVH and congestive heart failure. LVH also
results in susceptibility to myocardial hypoperfusion and ischemia as a result of disturbances in
coronary flow physiology, that likely reflects remodeling of coronary arteries [20-25].

Perivascular inflammation has been observed in hypertensive disease and congestive heart
failure (CHF) and may initiate fibrosis and coronary artery remodeling. Inhibition of
inflammatory responses tends to attenuate cardiac fibrosis in experimental models
[17,18,27,28]. In DOCA/salt-induced hypertensive rats, pharmacological targeting of
monocyte/macrophage accumulation ameliorated cardiac perivascular and interstitial fibrosis
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and reduced inflammatory marker expression, such as interleukin-6 (IL-6) and monocyte
chemotactic protein-1 (MCP-1) [17,18,27,28,30]. In a rat model of suprarenal aortic
constriction, antibody blockade of either intercellular adhesion molecule-1 (ICAM-1) or MCP-1
reduced early macrophage recruitment, and prevented the development of myocardial fibrosis
[17,28]. However, the triggers for initiation of perivascular inflammation in the setting of LVH
are poorly understood.

Accumulating evidence implicates platelets in vascular inflammation in a variety of settings.
Platelets, small cytoplasmic bodies that lack nuclei, are generated by megakaryocytes in bone
marrow. In settings of vascular injury or inflammation, platelets adhere to the subendothelial
matrix or endothelial cells. Subsequent platelet activation maintains hemostasis through
platelet-platelet interactions that form the primary platelet clot. Activated platelets express and
release granule contents. Activation-dependent surface expression of adhesive molecules, such
as P-selectin, serves to recruit leukocytes; inflammatory mediators released by platelets may
modulate leukocyte responses at sites of vascular injury [32,35,37,41-43]. Thus, in addition to
their essential role in hemostasis, platelets have been proposed to serve as important
mediators of vascular inflammation [33-40].

In this chapter, we investigated early cellular events that mediate perivascular inflammation
and coronary artery remodeling. We report that platelets and T lymphocytes are recruited to
coronary arteries after TAC and that both cell types may play unanticipated roles in modulating
perivascular

inflammation

and

fibrosis

in
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the

setting

of

LV

pressure

overload.

MATERIALS AND METHODS
Animals All procedures conformed to the recommendations of "Guide for the Care and Use of
Laboratory Animals" (Department of Health, Education, and Welfare publication number NIH
78-23, 1996) and were approved by the Institutional Animal Care and Use Committees at the
University of Kentucky. The C57BL/6J (B6), RAG-1-deficient (Rag1-/-) mice, and IL-10-deficient
(IL-10-/-) mice, were obtained from The Jackson Laboratory (Bar Harbor, ME). All the mice were
maintained on the C57BL/6J background.
Transverse aortic constriction Model Pressure overload of the LV was elicited by TAC in male
mice at the age of eight to 12 weeks. Sham surgery, in which a suture was passed around the
aorta but removed without tying, was performed as a control [98]. Mice were euthanized at
early (one day, three days, and seven days) and late (five weeks) time points after surgery. Left
ventricle function and coronary flow reserve were measured by echocardiography and Doppler
(Figure 2.1).
Doppler Studies Velocity of blood flow in the left and right carotid arteries and coronary artery
was measured as described previously [96,97] using a hand-held 20 MHz Doppler probe (Indus
Instruments, Houston, TX) before and after surgery, as well as the additional time points post
surgery.

The mice were anesthetized with isoflurane 1.5-2 %, and taped supine to a

temperature-controlled board. The board included electrocardiographic electrodes placed
under each limb and a heating pad under the body. Body hair was clipped and the skin was
moistened with water to improve sound transmission. The Doppler probe was placed on the
left and right sides of the neck at a 45° angle to detect flow velocity in the left and right carotid
arteries. For coronary flow, the probe tip was placed on the left chest at the level of the cardiac
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base and pointed horizontally toward the anterior basal surface of the heart to sense blood
flow velocity. The optimal Doppler flow velocity signals were obtained by adjusting the position
of the probe and the Doppler range gate depth of 2 mm (for carotid artery) or 2.5–3 mm (for
coronary artery), to obtain a maximal velocity signal. A computer-based Doppler signal
processor (Model DSPW, Indus Instruments,) was used to store the Doppler signals and for later
analysis. For left coronary artery flow, the baseline flow velocity was recorded at 1 % isoflurane
concentration. The hyperemic flow velocity was recorded during maximal vasodilatation
induced by 2.5 % isoflurane and after three minutes of isoflurane inhalation. Coronary artery
flow reserve was calculated as the ratio of hyperemic peak flow velocity to baseline peak flow
velocity.
Echocardiography Two-dimensional short and long axis views of the left ventricle were
obtained by transthoracic echocardiography performed five weeks post-TAC using a 45 MHz
probe (770) and the Vevo 770 Imaging System (VisualSonics, Toronto, Canada), under 1.5 %
isoflurane inhalation as described previously [1]. M-mode tracings were recorded and used to
determine LV end diastolic diameter (LVEDD), LV end systolic diameter (LVESD), and LV
posterior wall thickness in diastole (LVPWThD) over three cardiac cycles. LV fractional
shortening (FS) was calculated using the formula % FS= (LVEDD-LVESD)/LVEDD.
Histology Mice were weighed and hearts, lungs, livers and kidneys were dissected at days one,
three, seven and five weeks post surgery. Hearts were harvested, washed in PBS, and sectioned
at the level of the papillary muscle. The base of the heart was immersed in 4 % PFA for 24
hours, subsequently transferred to 70 % ethanol and embedded in paraffin. Multiple serial 5
µm sections (six – 10) were taken every 250 µm from the distal region of the heart from the
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base to the aorta. Slides (six – 10) were created that contain two sections every 250 µm
spanning the base of the heart. Slides from each heart were stained with H&E, Masson’s
Trichrome and picrosirius Red staining. The remaining slides were archived for later use.
Paraffin embedded IHC was done with a mouse-anti-mouse smooth muscle cell actin-α
antibody (Sigma A-5691). In brief, heart sections were first deparaffinized and placed in diluted
antigen unmasking solution (Vector, Burlingame, CA) for antigen retrieval using a decloaking
chamber (Biocare Medical, Concord, CA). Non-specific sites were blocked using mouse-onmouse IgG blocking reagent (Vector Labs) for one hour in room temperature. Slides were then
incubated with primary antibody for one hour at room temperature, followed by 30 minutes
with substrate solution (Vector Red substrate). CAT Hematoxylin (Biocare Medical) was used for
counterstaining. Finally, slides were dehydrated, mounted with DPX coverslip (Gallard
Schlesinger Industries) and covered by cover glasses. Positive staining was quantified using
Metamorph software.
IHC was performed on frozen sections using CD90.2 (1:100, BD PharmingenTM, San Diego, CA, ),
CD68 (1:200, Serotec), VCAM-1(1:50, BD PharmingenTM), PECAM-1(1:50, BD PharmingenTM),
CD8 (1:50, Serotec), CD19 (1:50, BD PharmingenTM), MPO (1:50, Abcam) and platelet antibody
(1:1000, Intercell). Briefly, the heart bases were directly embedded in OCT and frozen at -20 °C.
Blocks were cut into 10 µm sections and fixed with chilled acetone in -20 °C. To minimizing the
effect of endogenous peroxidases, slides were immersed in 1 % H2O2 in methanol for two
minutes at 40° C. Non-specific sites were blocked using 1.5 % serum from the secondary
antibody-derived animal for 15 minutes at 40° C. Slides were then incubated with primary
antibodies for 15 minutes at 40° C, the for 15 minutes with biotinylated secondary antibody,and
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then for 10 minutes with ABC detector (Vector Labs) at 40 °C. HRP substrate-chromogen
(Biomed) was used as the chromogen, and hematoxylin (Accurate Chemical & Scientific Corp.)
was used for counterstaining. Frozen slides were fixed with chilled acetone in -20 °C. Nonspecific sites were blocked using 1.5 % serum from (the secondary-antibody-derived animals)
for 20 minutes at RT. Slides were then incubated with PECAM-1 primary antibody (1:50, BD
PharmingenTM) at RT for one hour and a rhodamine-conjugated goat-anti-rat secondary
antibody (15 µg/ml, Jackson ImmunoResearch, West Grove, PA) at RT for 30 minutes. Slides
were viewed and images were taken using a Leica TCS SP5 laser scanning inverted confocal
microscope.
Immunostaining of targeted proteins was quantified in tissue sections from TAC mice and their
respective sham controls. For each antibody, isotope-matched non reactive IgG served as the
negative control. The percentage of the vessel area occupied by inflammatory cells was
measured from digital images using Metamorph software by personnel blinded to treatment.
Perivascular and interstitial fibrosis was measured from Masson’s Trichrome and picrosirius Red
stained slides. Vessel area was quantified using Metamorph software and reported as external
elastic laminar (EEL).
Quantitative PCR RNA samples were extracted from the apex of the heart (stored in RNA later, 80 °C) using TRIzol (Invitrogen, Grand Island, NY) as described previously [109]. RNA
concentration and quality were tested using OD

260 / 280

ratio by Biomate3 (Thermo Electron

Corporation, Waltham, MA) and also by examining the product on a 1 % agarose gel. The cDNA
synthesis was performed using High-Capacity cDNA Archive kit (Applied Biosystems, Foster City,
CA), starting with 1 µg RNA in 20 µl reaction system. Quantitative real-time PCR was done using
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Taqman Universal Master Mix and Assays-on Demand primers and probes (Applied Biosystems)
and the ABI 7500 system. 18S RNA was used as an endogenous control. An embryo RNA
standard was used as a positive control. Results were expressed as mean fold changes of gene
expression relative to sham-operated C57Bl/6 mice or control antibody injected TAC mice using
2-ΔΔCT method [109].
Flow Cytometry Fifty µl blood was collected in 0.32 % citrate and incubated with anti-Mac-1
antibody (PE conjugated, BD Pharmingen) at a final concentration of 20 µg/ml or rat IgG (PE
conjugated, Emfret) as an isotype control in the presence of 1 µM RGDS peptide to prevent
platelet aggregation. CD41 Ab (FITC conjugated, BD Pharmingen™) was added to give a final
concentration of 20 µg/ml. To activate platelets, 150 µM PAR4 activating peptide (Anaspec,
Fremont, CA) was added. After 15 minutes of incubation, 1 ml of Lyse/Fix solution (BDTM
Phosflow) was added to each sample. Platelet-leukocyte aggregates were quantified using
FACalibur flow cytometer (Becton Dickinson) and analyzed by CellQuest software.
To measure platelet activation by flow cytometry, blood was collected into 0.32 % citrate and
diluted further in Tyrode’s Buffer with 0.35 % BSA and 1 mM MgCl2. The diluted blood was
incubated with 60 µg/ml FITC anti-fibrinogen (DAKO) or 20 µg/ml FITC anti-P-selectin antibody
(BD Sciences) and the indicated agonist, for 10 minutes in the dark. The reaction was stopped
by the addition of Tyrode’s buffer and paraformaldehyde. Samples were quantified by flow
cytometer by gating on platelet populations identified by forward and side-scatter properties.
Whole Blood Aggregation Aggregation was studied in whole blood using a Multiplate®, Platelet
Function Analyzer (Dynabyte, Munich, Germany). 300 µl of whole blood was diluted 1:1 with
normal saline (0.91 %) and 1 mM MgCl2 solution and incubated for 3 minutes at 37 °C, prior to
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the addition of 6.5 µM ADP. Aggregation units (AU) and the area under the curve (AUC in AU *
minutes) was calculated based on measurements of electric impedance.
Mouse Plasma Collection. Mouse blood was collected into EDTA–coated tubes, immediately
centrifuged at 2000 g for 10 minutes at RT, and plasma stored at -80 °C.
Mouse Cardiac Tissue Extraction The base of the LV was dissected (2 mm × 2 mm pieces) in 250
µl of PBS containing protease inhibitors (Pierce), homogenized using Omni tissue homogenizer,
and then sonicated for 10 seconds. Following centrifugation (14,000 rpm for 15 minutes at 4
°C), approx 200 µl of supernatant was diluted with 200 µl PBS containing protease inhibitors.
Luminex Assay Inflammatory cytokine/chemokine levels in mouse plasma and extracts of
cardiac tissue were measured by Luminex bead analyte assay using Milliplex MAP Kit according
to the manufacturer’s instructions (Millipore)
Culturing and treatment of myocardial fibroblasts Primary myocardial fibroblasts were isolated
from C57BL/6 male mice by mincing hearts in 1ml of dispase solution. After fully mincing, 4 ml
dispase solution was added, the sample placed at 37°C, and pipetted up and down at 15
minutes. After 30 minutes, 5ml HBSS+ solution was added to neutralize the dispase. The cell
suspension was then centrifuged at 2,200 rpm for eight minutes. The cell pellet was saved and
resuspended in plating medium (low glucose DMEM + 10% FBS +Penicillin Streptomycin). Cells
from one heart were settled in one, six-well plate over night, washed the next day, and added
with fresh media. The attached myocardial fibroblasts were cultured for seven-10 days to reach
a 70 % to 80 % confluence before treatment.
Washed platelets were isolated from ACD buffered C57BL/6 male mice blood. 1.5 × 109
platelets were stimulated using 1 U/ml of thrombin at 37°C for 10 minutes, neutralized with 1
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U/ml hirudin. The suspension was then centrifuged at 3000g at 4°C for 10 minutes and
supernatant was collected. Myocardial fibroblasts were treated with 1 ml/well of either platelet
releasate or buffer (both diluted 1:5 in medium with 0.1% FBS). Cells were harvested at six
hours or 24 hours, and RNA was isolated using RNeasy Plus mini kit (Qiagen). The cDNA
synthesis and quantitative PCR were performed as described before.
Statistical analysis All results were expressed as mean ± standard error of the mean (SEM).
Statistical significance within strains was determined using t-test or two way ANOVA with
multiple pair-wise comparisons as appropriate. The Mann-Whitney test was used for
nonparametic analysis. Statistical analysis was performed using Sigma-STAT software, version
3.5 (Systat Software, Inc.). A p-value of less than 0.05 was considered significant.
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RESULTS
TAC is accompanied by early pericoronary inflammation
Transverse aortic constriction (TAC) induces an acute and persistent increase in proximal aortic
and LV pressure, manifested by an elevation in the ratio of the right to left (R / L) carotid peak
flow velocity (Figure 2.1A). Though cellular and molecular events that are not well understood,
LV pressure overload in mice elicits significant perivascular and interstitial cardiac fibrosis at five
weeks post-surgery [98] (Figure 2.1B). As reported by Hartley and colleagues [95-97], we
observed a decline in coronary flow reserve (CFR) after TAC, indicating dysfunction of the
coronary arteries (Figures 2.1C and 2.1D). In the present study, we investigated the
contribution of early perivascular inflammation to coronary artery remodeling and perivascular
fibrosis in the setting of pressure overload. As early as one day post-surgery, inflammatory cells
accumulated along the left coronary arteries (Figure 2.2). Both macrophages (CD68+; Figures
2.2A and 2.2B) and T-lymphocytes (CD90.2+; Figures 2.2A and 2.2C), in the vessels increased by
approximately four-fold during the first week post-TAC. The CD8 staining confirmed the
presence of T cells. However, B cells stained by CD19 were not detected after TAC (Figure 2A).
The expression of vascular cell adhesion molecule 1 (VCAM-1) and myeloperoxidase (MPO)
were also increased after TAC (Figure 2.2A). The inflammatory infiltration in the left coronary
arteries was accompanied by a perturbation in the endothelium, as evidenced by discontinuous
platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) staining (Figure 2.3).

To provide insight into the underlying mechanisms for inflammation and remodeling early after
TAC we measured RNA or protein levels of candidate cytokine mediators, such as monocyte
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chemotactic protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), tumor necrosis
factor-α (TNF-α), interleukin-6 (IL-6), which were known to contribute in other hypertrophy
models [17,18,27,28,30]. We also measured levels of growth factor β-1 (TGFβ-1)
[178,180,183,191] and vascular endothelial growth factor (VEGF), which have demonstrated
roles in fibrosis and angiogenesis in the setting of cardiac hypertrophy. Additionally, because
our IHC data indicated early T lymphocyte accumulation, we measured RNA or protein levels of
IL-1β, IL-10, interferon-γ (IFN-γ) in order to define the T lymphocyte subtypes involved. At seven
days after TAC, MCP-1 (Figure 2.4A) and VEGF (Figure 2.4B) increased in cardiac tissue.
Additionally, IL-10 mRNA expression increased more than three-fold in LV between three and
seven days after TAC (Figure 2.4C). In the first several days after TAC, there were no significant
changes in TNF-α, ICAM-1, TGFβ-1 or IFN-γ mRNA levels in LV (data not shown). Plasma
cytokines, including IL-1β, IL-10, VEGF, IFN- γ, TNF-α, and MCP-1, also did not appreciably
change early after TAC, although a trend towards higher plasma IL-6 level post-TAC was noted
(data not shown).

The effects of thrombocytopenia on TAC-induced LV remodeling
Platelets often contribute to perivascular inflammation [33-40], and enhanced platelet
activation is found in patients with cardiac hypertrophy and heart failure [32,41]. Therefore, we
investigated the contribution of platelets to the inflammatory response that accompanies TAC.
At seven days after surgery, platelet counts in whole blood were higher in TAC animals (1299 ±
226 / nl) than sham mice (803 ± 191 / nl; P < 0.001). Pressure overload led to platelet
deposition along the damaged endothelial layer at three and seven days after TAC surgery
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(Figure 2.5A). The platelets appeared to accumulate in association with leukocytes, including
macrophages (Figure 2.5B). Systemic platelet activation can be detected in settings of vascular
inflammatory diseases, such as atherosclerosis [192-195]. One measure of platelet activation is
the presence of circulating platelet-leukocyte aggregates in systemic circulation. In blood
collected at seven days after sham surgery, 25 ± 3 % of the leukocytes had attached platelets,
whereas 39 ± 7 % of the leukocytes had attached platelets in blood from TAC mice (P = 0.106).
Interestingly, at three and seven days after surgery, agonist-induced platelet aggregation in
whole blood and platelet P-selectin expression were lower in TAC than in sham-treated animals
(data not shown), suggesting that the platelets remaining in circulation post-TAC may be less
responsive to agonists.

To identify a role for platelets in TAC-induced vascular remodeling, thrombocytopenia was
induced by treating mice with a glycoprotein Ibα (GPIbα) antibody that promotes platelet
clearance through an Fc fragment-independent pathway [196]. Following anti-GPIbα IgG
treatment, the median platelet count of 70 / nL (25 – 75 % CI: 50 – 101 / nL) was substantially
lower than the median platelet count of 1362 / nL observed in mice treated with non-immune
IgG (25 – 75 % CI: 1070 – 1567 / nL; P < 0.001). White blood cell count was normal, with no
lymphopenia noted after administration of anti-GPIbα IgG. The effect of antibody treatment on
platelet function was confirmed by measuring tail-bleeding time. The median bleeding time was
>600 seconds in mice treated with anti- GPIbα IgG (600 – 660 seconds; 25 – 75 % CI) and 70
seconds (55 – 77 seconds; 25 – 75 % CI) in mice treated with non-immune IgG (P < 0.001).
Depletion of platelets prior to TAC did not significantly alter macrophage accumulation but
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reduced the accumulation of T lymphocytes in the coronary arteries after TAC (from a median
of 524 µm2 to 122 µm2; P = 0.031, Figures 2.5C and 2.5D). In association with lower T-cell
accumulation in thrombocytopenic mice, IL-10 levels in LV were 50 % lower in mice treated
with anti-GPIbα IgG (Figure 2.5E).

To determine the long-term consequences of platelet depletion and resultant reductions in Tlymphocytes and IL-10 in the vessel wall, we examined coronary arteries at five weeks after
TAC. In thrombocytopenic mice, the large coronary arteries contained significantly more
smooth muscle cell (SMC) α-actin, consistent with an effect on vascular remodeling (Figures
2.6A and 2.6B). In addition, mice treated with anti-GPIbα IgG had a trend towards an increase in
perivascular fibrosis (Figure 2.6C). These findings were not due to alterations in cardiac size or
function since heart weight to body weight ratio (HW: BW) and left ventricular internal
diameter in diastole (LVIDd), posterior wall thickness (PWt), and fractional shortening (FS) as
measured by echocardiography, were similar in control and thrombocytopenic mice (data not
shown).

In addition to recruiting inflammatory cells, platelets may release mediators that directly affect
cardiac fibroblasts and thereby influence perivascular fibrosis. Therefore, the effect of platelet
releasate on cardiac fibroblasts was investigated. Releasate was prepared from thrombin
activated platelets and incubated with primary cultures of murine cardiac fibroblasts. Following
6 hours of exposure to platelet releasate, expression of MMP9 mRNA significantly increased by
15.5 ± 0.6 fold (Figure 2.7) and remained elevated at 24 hours (Figure 2.7). Platelet releasate
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also increased α-SMA expression at 24 hours. In addition, TGFβ-1 signaling appeared to be
enhanced, in that the downstream targets bone morphogenic protein 7 (BMP7) and connective
tissue growth factor (CTGF) were 6.6 ± 2.4 and 3.8 ± 0.1 fold higher following exposure to
platelet releasate.

Absence of lymphocytes exaggerates left coronary remodeling.
Our results indicated that T (but not B), lymphocytes accrue in the vessel wall as part of the
inflammatory response after TAC and that depletion of platelets reduced their perivascular
accumulation. To define the impact of lymphocytes on coronary remodeling we used Rag1-/mice. Rag1 encodes the recombination activation gene 1 that catalyzes V(D)J recombination, an
essential step for the generation of immunoglobulins and T lymphocyte receptors. As a
consequence, Rag1-/- mice lack mature B and T lymphocytes [197]. The absence of lymphocytes
in Rag1-/- mice did not significantly alter the number of macrophages that accumulated in the
coronary arteries seven days after TAC (data not shown). The absence of lymphocytes also did
not alter the development of LVH, as HW: BW was not significantly different in wild-type and
Rag1-/- mice at five weeks post-TAC (Table 2.1). Likewise, overall coronary artery remodeling, as
measured by the area of the vessel within the external elastic lamina, was similar in wild-type
and Rag1-/- mice after TAC (Figures 2.8A and 2.8B). However, lumen area was 1.32-fold smaller
in Rag1-/- coronary arteries after TAC, with a concomitant increase in collagen content.
Quantification of Masson’s Trichrome (Figure 2.8C) and picrosirius red staining (Figure 2.8E)
indicated that Rag1-/- mice had less perivascular fibrosis (Figure 2.8D) and collagen content
(Figure 2.8F) at baseline but greater levels after TAC than that observed in wild-type mice.
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Thus, the fold increase in perivascular fibrosis (11-fold, P = 0.031, Figure 2.8D) and collagen
content (43-fold, P = 0.008, Figure 2.8F) was significantly higher in Rag1-/- mice post-TAC.
Interestingly, despite these histological changes, the Rag1-/- mice demonstrated preserved CFR
after TAC. CFR was 1.83 ± 0.15 in wild-type mice that underwent sham surgery (n = 7) and 1.72
± 0.23 in sham-treated Rag1-/- mice (n = 3). Following TAC, CFR declined to 1.22 ± 0.31 in wildtype mice (n = 13; P < 0.05). However, CFR was not significantly different in sham and TAC Rag1/-

mice (1.57 ± 0.16; n = 7), suggesting that despite the smaller lumen size and greater collagen

content, the function of the coronary arteries after TAC was preserved in the absence of
lymphocytes. At baseline, in comparison to wild-type mice, Rag1-/- mice had reduced LV
function which did not decline further following TAC (Table 2.2).

IL-10 may play a protective role in LV remodeling
Platelets can influence the function of T-cells by eliciting the release of IL-10 from dendritic cells
[198]. The finding that thrombocytopenia lowered both T-cell infiltration and IL-10 levels after
TAC suggested that platelets may be influencing T-cell-mediated events in an IL-10-dependent
manner in this model. Therefore, we sought to determine if IL-10 deficiency recapitulated
aspects of the phenotype observed in thrombocytopenic or lymphopenic mice.

Cardiac

hypertrophy, as assessed by HW: BW ratio, was not significantly different in IL-10-/- and wildtype mice after TAC (7.7 ± 2.0 and 7.1 ± 1.3, respectively, P = 0.596, NS). However, IL-10-/- LV
displayed substantial perivascular fibrosis as detected by Masson’s Trichrome staining (Figure
2.9A) with levels (11,600 ± 2000 µm2, mean ± sem; n = 5) similar to those observed in
thrombocytopenic and Rag1-/- mice post-TAC and was significantly higher than B6 mice. The IL48

10-/- TAC mice also displayed evidence of exaggerated remodeling as measured by SMC α-actin
staining, with a similar level of B6 mice (Figure 2.9B).
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Table 2.1 Organ and body weight in WT and Rag1-/- mice five weeks after TAC or sham surgery
Genotype Treatment n
BW (g)
HW: BW
LiW: BW
LuW: BW
KiW: BW
WT
WT

sham

3

24.8 ± 2.1

5.2 ± 0.84

44.9 ± 3.0

6.1 ± 0.4

13.7 ± 1.2

#

41.8 ± 5.4

6.6 ± 0.5

14.1 ± 0.7

TAC

7

25.0 ± 1.3

6.9 ± 0.2

Rag1

-/-

sham

3

29.7 ± 1.5

5.6 ± 0.4

52.6 ± 1.7

5.1 ± 0.2

12.7 ± 1.0

Rag1

-/-

TAC

7

27.7± 1.7

6.7 ± 0.2*

48.7 ± 1.1

5.5 ± 0.2

12.6 ± 0.5

Results are presented as mean ± sd; BW = body weight, HW = heart weight, LW = liver weight,
LuW = lung weight, KiW = kidney weight. Two way ANOVA statistics show significant differences
in the ration of heart weight to body weight between TAC and sham groups in B6 and Rag1-/mice. # P < 0.001, * P < 0.05 vs sham controls.
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Table 2.2 Echocardiographic analysis of heart size and function in WT and Rag1-/- mice five
weeks after TAC or sham surgery

genotype

treatment

n

FS (%)

WT

sham

3

39 ± 1.8

WT

TAC

7

25.3 ± 1.2*

Rag1-/-

sham

3

32.2 ± 1.8#

Rag1-/-

TAC

7

28.4 ± 1.8

FS = fractional shortening; * P < 0.05; # P < 0.001 vs WT sham control
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Figure 2.1 TAC-induced LV pressure overload stimulates left coronary remodeling and
dysfunction in wild-type C57BL/6 male mice.
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A) Ratio of right/left (R / L) peak Doppler flow velocity in carotid arteries before and at
indicated times after TAC (closed circle) or sham (open circle) surgery. B) Representative images
of Masson’s Trichrome stained left ventricle showing left coronary arteries five weeks after
sham or TAC surgery. (Top bar = 2323 µm; bottom bar = 230 µm). C) Impact of sham (open) and
TAC (closed) surgery on coronary flow velocity in mice anesthetized with 1 % (baseline
conditions; circles) and 2.5 % (hyperemic conditions; triangles) isoflurane. D) Coronary flow
reserve (CFR), measured as the ratio of flow velocity in mice anesthetized with 2.5 % isoflurane
to that observed in mice anesthetized with 1 % isoflurane, declines in TAC (closed circle) but not
sham (open circle) mice, indicating vascular dysfunction.
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Figure 2.2 TAC elicits an early inflammatory response in wild-type (C57BL/6) male mice.
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A) Immunohistochemical staining of inflammatory cells and adhesion molecules in LV sections
from wild-type male mice subjected to sham or TAC surgery and sacrificed at different time
points (D = days). Positive staining is in red-brown (mag. 40X; Bar = 70 µm T lymphocytes are
indicated by CD90.2 and CD8; CD19 is a B lymphocyte marker. VCAM is an endothelial
inflammatory marker and myeloperoxidase (MPO) an enzyme stored and released by
neutrophils and macrophages. B) and C) Quantification of the accumulation of macrophage
(CD68) and T lymphocyte (CD90.2), as measured by area of positive staining in and around the
coronary arteries, at different time points following sham (open circles) and TAC (closed circles)
surgery. Values are presented as mean ± SEM. The images are representative of those obtained
in the following numbers. For macrophages: TAC day one, n = 5; TAC day three, n = 7; TAC day
seven, n = 9; sham day one, n = 3; sham day three, n = 4; sham day seven, n = 5. For
lymphocytes: TAC day one, n = 7; TAC day three, n = 6; TAC day seven, n = 6; sham day one, n =
4; sham day three; n = 5; sham day seven, n = 5. *P < 0.05 versus same time point in sham.
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Figure 2.3 Endothelial disruption at three and seven days after TAC surgery.
Confocal (left and middle panel) and IHC (right panel) images of PECAM (CD31) staining along
the lumen of left coronary arteries at three days after sham surgery (sham D3) and at three
(TAC D3) and seven days (TAC 7D) after TAC surgery. CD31 staining appears continuous along
the luminal side in sham mice and discontinuous along similar vessels in TAC mice. Bar = 70 µm.
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Figure 2.4 Upregulation of inflammatory markers after TAC in wild-type mice.
Levels of MCP-1 (A) and VEGF (B) were measured in homogenized LV at seven days after sham
(n = 6) or TAC surgery (n = 8) by Luminex assay. Protein expression (pg / ml) in the homogenate
is reported for each individual mouse, and boxes indicated median and 95 % CI. (C) RNA was
isolated from LV apex at one to seven days after TAC (n = 3 – 7 per time point). IL-10 mRNA
levels were measured by qPCR and values normalized to the sham value at day one, which was
set at 100 % expression, and presented as mean ± SD. *P < 0.05 versus sham.

57

Figure 2.5 Platelet accumulation and effects on perivascular inflammation.
A) Immunohistochemical staining for platelets three days after TAC (mag. 40X). B) Platelet
deposition colocalized with macrophages in coronary arteries at seven days after TAC (TAC D7).
Serial sections through coronary arteries were stained with antibodies to platelets (top), CD68
(middle) and CD31 (bottom). (mag. 40X; Bar = 70 µm). Area of positive perivascular staining for
C) macrophages (vessel number = n, anti-GPIbα IgG n = 23, non-immune IgG n = 18) and D) T
lymphocytes (vessel number = n, anti-GPIbα IgG n = 26, non-immune IgG n = 18) three days
after TAC. *P = 0.05. E) Expression of inflammation markers in LV apex at three days post-TAC
was measured by qPCR (mice number = n, anti-GPIbα IgG n = 13, non-immune IgG n = 10)
presented as mean ± SD.
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Figure 2.6 Thrombocytopenia promotes coronary vessel remodeling and perivascular fibrosis
after TAC.
A) Representative images (mag. 40X) and B) quantification of α-smooth muscle actin staining in
coronary arteries of thrombocytopenic (anti-GPIbα IgG treated) and control (non-immune IgG
injected) mice five weeks after TAC surgery (vessel number = n, anti-GPIbα IgG n = 11, nonimmune IgG n = 5). *P < 0.05. C) Area of pericoronary fibrosis thrombocytopenic and control
mice five weeks after TAC (vessel number = n, anti-GPIbα IgG n = 10, non-immune IgG n = 5).
Fibrosis was identified by Masson’s Trichrome stain and reported as area mean ± SEM.
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Figure 2.7 The effects of platelet releasate on myocardial fibroblasts.
qPCR was performed to detect the differences of mRNA expression in cardiac fibroblasts
exposed to platelet releasate (dark bars) or buffer (open bars) for six (left) or 24 (right) hours.
The values were normalized to the buffer-treatment group at the same time point, which was
set at fold increase and presented as mean ± SD.
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Figure 2.8 Enhanced TAC-induced coronary remodeling in the absence of lymphocytes.
A) H&E staining (mag. 20X) and B) measurement of vessel area inside the external elastic
laminar in wild-type (WT) and Rag1-/- male mice five weeks after sham or TAC surgery (TAC: WT
n = 10, Rag1-/- n = 17. Sham: WT n = 9, Rag1-/- n = 6). C) Masson’s Trichrome staining and D)
quantification of pericoronary fibrosis formation in WT and Rag1-/- male mice five weeks after
surgery reported as area mean ± sem (TAC: WT n = 10, Rag1-/- n = 13. Sham: WT n = 9, Rag1-/- n
= 6). E) Picrosirius red staining and F) quantification of pericoronary collagen deposition in WT
and Rag1-/- male mice five weeks after surgery reported as area mean ± sem (TAC: WT n = 9,
Rag1-/- n = 19. Sham: WT n = 7, Rag1-/- n = 7). *P < 0.05. Bar = 145 µm.
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Figure 2.9 TAC-induced coronary remodeling in the absence of IL-10.
A) Representative sections stained with Masson’s Trichrome (MT) and visualized at 40X mag.
five weeks after sham or TAC surgery (left) and measurements of perivascular fibrosis area
(sham n = 5; TAC n = 5). B) SMC α-actin staining five weeks after sham or TAC surgery (left) and
measurements of vessel area occupied by SMC α-actin (right). *P < 0.05. Bar = 70 µm.
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Figure 2.10 Model of TAC-induced early inflammatory responses in which platelets and
inflammatory cells are recruited and contribute to the subsequent development of intimal
hyperplasia and fibrosis.
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SUMMARY

To summarize the work accomplished in CHAPTER 2: we have observed and characterized the
pericoronary accumulation of macrophages, T lymphocytes and platelets early after TACinduced LV pressure overload. Platelet-depleted mice and lymphocyte-deficient mice revealed
both platelets and lymphocyte play a protective role in TAC-induced coronary remodeling,
likely, mediated by IL-10.

Copyright © Fanmuyi Yang 2012
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CHAPTER 3: PLATELET RELEASATE PROMOTES CARDIAC HYPERTROPHY FOLLOWING LEFT
VENTRICULAR PRESSURE OVERLOAD
INTRODUCTION
As a consequence of chronically elevated afterload, hypertension stimulates an increase in left
ventricular mass or hypertrophy (LVH) and fibrosis, with resultant LV systolic and/or diastolic
dysfunction. Hypertensive left ventricular hypertrophy is accompanied by perivascular
inflammation, which may contribute to cardiac remodeling. In animals, LV pressure-overload
can be modeled by transverse aortic constriction (TAC). We and others have reported that
inflammatory cells, including macrophages, T lymphocytes and platelets, accumulated along
and within the coronary arteries within days after TAC. The early accumulation of these cells
may influence subsequent arterial and ventricular remodeling.
In addition to direct cell-cell interactions, inflammatory cells communicate with the surrounding
tissue by releasing cargo stored within granule compartments.

Platelets, for example, have

three distinct types of secretory vesicles: α-granules, dense granules and lysosomes, which are
a rich source of cytokines, chemokines and growth factors. Components of platelet releasate
e.g. serotonin, TGFβ-1, S1P, have been implicated as regulators of pathologic cardiac
remodeling. Thus, it is possible that platelet deposition in the setting of LV pressure overload
could influence the tissue response. To investigate the role of granular secretion in LVH and
cardiac remodeling, we made use of mice that lack the ability to release cargo from granules.
Platelet granule secretion requires vesicular docking, tethering, priming and membrane fusion.
Vesicular fusion is driven by soluble NSF attachment protein receptors (SNARE) complexes,
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composed of a VAMP, a Syntaxin, and SNAP-23 proteins [101,119]. Members of the Rab family
of Ras GTPases are essential for membrane tethering that occurs prior to fusion [115]. The
Rab27 effector protein Munc13-4 appears to play an important role in granular secretion
[115,150,154-159]. Several mutations, including a single point mutation in Munc13-4, can
result in type 3 familial hemophagocytic lymphohistiocytosis (FHL3), which is characterized by
hepatosplenomegaly, anemia, and thrombocytopenia [150]. Unc13dJinx (Jinx) mice carry a
mutation in Unc13d, the murine homolog of Munc13-4, and display secretion defects in natural
killer cells, cytotoxic T lymphocytes, neutrophils, mast cells and platelets [153-158] and features
of FHL3 [162]. Neutrophils from Jinx mice have alterations in secretion of MMP-9 and MPO,
whereas overexpression of Munc13-4 enhances MMP-9 secretion in human neutrophils [156].
Jinx platelets display defects in dense granule, α-granule and lysosome secretion upon
thrombin stimulation in Jinx mice. The addition of Munc13-4 protein restores secretion to
mutant platelets and increases secretion in wild-type platelets [154]. The relatively low levels of
Munc13-4 in platelets and the partial secretion defects in heterozygous mice have led to the
suggestion that the protein may be the rate limiting factor in platelet granular secretion [154].
In this report, we used Jinx mice to determine the contribution of granular secretion to LV
remodeling following TAC. Chimeric mice were created by bone marrow transplantation to
identify a role for cargo release from bone marrow derived cells. While the loss of Munc13-4
did not affect the initial development of LVH, sustained hypertrophy did not occur in the
absence of Munc13-4 in bone marrow derived cells. Cardiac hypertrophy could be restored by
administration of platelets or platelet releasate to chimeric mice. These results suggest that
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sustained LVH in the setting of pressure overload depends on factor(s) secreted from bone
marrow cells, likely from platelets.
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MATERIALS AND METHODS
Mice. All procedures conformed to the recommendations of Guide for the Care and Use of
Laboratory Animals (Department of Health, Education, and Welfare publication number NIH 7823, 1996) and were approved by the Institutional Animal Care and Use Committee. C57BL/6
mice were purchased from Jackson laboratories. Unc13-dJinx (Jinx) mice were generously
provided by Dr. Sidney W. Whiteheart. The Jinx mutation was originally identified in a MCMV
susceptibility screen performed in offspring of C57BL/6 mice that had been subject to random
N-ethyl-N-nitrosourea (ENU)-induced germline mutagenesis [199]. Mice were housed in cages
with HEPA-filtered air in rooms on 12-hour light cycles and fed Purina 5058 rodent chow ad
libitum.
Bone Marrow Transplantation. Bone marrow cells were isolated from 8-12 week-old donor
mice by flushing femurs and tibias with 5 ml ice-cold media (RPMI, 10 mM HEPES, 25 units/ml
heparin, 5% FBS) using a 27.5 gauge needle. The cells were washed by centrifugation (453g, at
4 °C for 10 minutes), RBCs lysed in hypotonic saline, and the reminder of the cells suspended in
PBS containing 2% heat-inactivated FBS at 5 × 107 cells / ml. Six to 8 week-old recipient mice
were irradiated twice (450 rad) 3 hours apart, and then injected with 5 × 106 cells within 4
hours after the second irradiation.
Transverse Aortic Constriction (TAC): TAC and sham surgery was performed as previously
described [200].
Washed Platelet Preparation. Blood was collect into ACD (2.5% sodium citrate, 0.4% citric Acid,
1.5% D-glucose) anticoagulant supplement with 1 µM PGE1 and diluted with normal saline prior
to centrifugation (201 x g for 10 minutes at room temperature) to obtain platelet-rich
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plasma/saline. After washing red blood cells an additional time, supernatants were pooled,
supplemented with 1 µM PGE1, and centrifuged to pellet the platelets (974g for 10 minutes at
room temperature). The platelet pellet was washed by resuspension in citrate-glucose-saline
buffer, pH 6.5, and centrifugation. Washed platelets were resuspended at 1×109/mL in Tyrode’s
buffer (NaHCO3 12mM, NaCl 138mM, D-glucose 5.5mM, KCl 2.9mM, MgCl2.6H2O 2mM,
NaH2PO4.H2O 0.42mM, HEPES 10mM), pH 7.4.
Platelet Aggregation. Platelets were diluted to 1 - 3×108/mL in Tyrodes buffer and allowed to
rest for at least 30 min. Aggregation was performed at 37 °C in a Chronolog dual chamber
lumiaggregometer in silicon-coated cuvettes with stir bars.
Platelet Releasate. Washed platelets (1 × 109/mL) suspended in Tyrode’s buffer were preincubated at 37 °C for 10 minutes and stimulated with thrombin (0.125 U/mL) for 10 minutes at
37 °C. To measure TGFβ-1, the suspension was centrifuged (14,000 g for 20 minutes in 4 °C) to
collect supernatant and platelet pellets.

Releasate to inject into mice was obtained by

centrifugation at 3,000 x g for 10 minutes at 4 °C.
Lipid Extraction and S1P Determinations were performed as described previously [201]. 2 mL
methanol, 1 mL of chloroform and 450 μL of 0.1 M HCl was added into 8 mL borosilicate glass
tube with addition of 50 μl plasma sample from each mouse. 50 μl of C17 S1P was also added as
internal standard. The mixture was vortexed for 5 minutes and placed in 4 °C overnight. 1 mL
chloroform and 1.3 mL 0.1 M HCl were added and the mixture was vortex for 5 minutes to
separate phases. The tubes were centrifuged at >3,000 x g for 10 minutes. The lower phase was
transfered to 4 mL screwed-cap tube using a Pasteur pipette. Samples were evaporated to
dryness under N2 using N-evap in fume hood. 100 μl of methanol was added to each tube
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which was then vortexed and stand for 10-15 minutes at room temperature before transferred
to autosampler insert vial for mass spectrometry study. Analysis of S1P, sphingosine and
hexadecenal (as its semicarbazone derivative) were accomplished using a Shimadzu UFLC (ultrafast liquid chromatography) coupled with an ABI 4000-Qtrap hybrid linear ion trap triple
quadrupole mass spectrometer in MRM (multiple reaction monitoring) mode using C17-S1P.
Statistical Analysis All results were expressed as mean ± standard deviation (SD). Statistical
significance within strains was determined using t-test or two-way ANOVA with multiple pairwise comparisons as appropriate. In t-test, if samples failed the normality test, Rank t-test were
used. In some cases of two-way ANOVA, data was Log-transformed to be normally distributed.
Statistical analysis was performed using Sigma-STAT software, version 3.5 (Systat Software,
Inc.). A p-value of less than 0.05 was considered significant.
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RESULTS
To create animals with impaired cargo release from hematopoietic cells, wild-type C57BL/6
(WT) male mice were lethally irradiated and reconstituted with bone marrow isolated from Jinx
mice, which lack functional Munc13-4 (Jinx>WT). WT mice that received WT marrow (WT>WT)
were used as the controls. Immunoblot analysis confirmed the absence of Munc13-4 in
platelets from WT mice reconstituted with Jinx cells (Jinx>WT) (Figure 3.1). No difference in
blood cell counts was observed in the chimeric mice (Table 3.1).
Lack of Munc13-4 does not alter early response to pressure overload.
At 6 – 7 weeks after bone marrow transplantation, mice were subjected to sham or TAC
surgery. Prior to surgery, cardiac function was similar in WT mice that had received WT marrow
(WT>WT) and Jinx marrow (Jinx>WT) (Table 3.2).

Our previous findings indicated that

inflammatory cells and platelets accumulate along coronary vessels and within ventricular
tissue within days after pressure overload. Both cell types have been implicated by us and
others as modulating cardiac remodeling, and release of granule contents is one mechanism by
which these cells could influence the response to pressure overload. Therefore, we examined
the consequences of lack of Munc13-4 in bone marrow derived cells early after TAC. Bone
marrow transplant did not affect the initial hypertrophic responses at Day 7 after TAC. The
heart weight : body weight (HW: BW) ratio in WT>WT mice was 6.67 ± 0.69 mg/g following TAC
which is higher than the 5.48 ± 0.31 mg/g observed in sham-operated controls (P<0.001) and
similar to that previously reported for WT not subjected to irradiation and transplantation [98].
Jinx>WT chimeric mice that underwent TAC also had significantly higher HW: BW ratios than did
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sham counterparts. (6.38 ± 0.85 versus 5.21 ± 0.27; P<0.001). The extent of early cardiac
hypertrophy in the Jinx chimers was similar to that observed in WT>WT mice (Figure 3.2A). The
development of cardiac hypertrophy in the setting of pressure overload is accompanied by fetal
gene reprogramming and increased mRNA expression of Nppa, Nppb, Myh7 and Acta1. Both
WT>WT and Jinx>WT mice exhibited increases of fetal gene expression at 7 days after TAC
(Figure 3.2B). Early inflammatory cell accumulation was unaffected by the loss of Munc13-4 in
hematopoetic cells (Figure 3.2C). These results indicate that the initial response to pressure
overload does not require Munc13-4-dependent events in bone marrow cells.
Attenuated cardiac hypertrophy 5 weeks after TAC in mice with defects in granule cargo
release from hematopoietic cells.
To determine if granule secretion contributed to the progression of cardiac hypertrophy, the
response in mice with WT or Jinx marrow was examined at five weeks after surgery. Blood
counts for the mice at this time point are presented in Table 3.3. As expected, WT>WT mice
had a significantly higher HW: BW ratio than did sham-operated WT>WT animals (7.6 ± 2.3 vs.
5.3 ± 0.3; P = 0.044; Table 3.4). WT>WT mice also had a significant increase in their LV posterior
wall thickness following TAC (1.3 ± 0.2 vs. 0.8 ± 0.1 mm in sham-operated controls; P = 0.004;
Table 3.4).

In contrast, WT mice that were reconstituted with Jinx marrow displayed a less

robust increase in cardiac mass at 5 weeks after TAC. While the absolute HW: BW ratio was
higher in Jinx>WT that underwent TAC surgery than in sham controls, the difference did not
reach statistical significance (6.7 ± 1.0 vs. 5.6 ± 0.6; P = 0.32). The same was observed with LV
posterior wall thickness (0.9 ± 0.3 vs. 0.8 ± 0.1 mm; P = 0.685) (Table 3.4). There was a
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statistically significant difference in HW: BW ratio in the WT>WT and Jinx>WT mice after TAC,
indicating more robust development of cardiac hypertrophy in mice expressing Munc13-4 in
marrow cells. Masson trichrome staining of heart sections confirmed smaller left ventricular
size in WT mice with Jinx marrow cells as compared to WT mice that received WT marrow
(Figure 3.3A). These results suggest that the absence of Munc13-4 in hematopoietic cells
protects from cardiac hypertrophy at late times after pressure overload.
To determine if absence of hypertrophy at 5 weeks after TAC in Jinx>B6 mice was due to a lack
of cardiomyocyte hypertrophy, histomorphometric analysis was performed on LV sections
stained with PAS. In comparison to cell size in hearts from B6>B6 mice after TAC, the
cardiomyocytes in Jinx>WT mice were 3-fold smaller after TAC (Figure 3.3B). As was observed
at 7 days post-TAC, upregulation of Nppa, Nppb, Myh7 and Acta1 occurred in both WT>WT and
Jinx>WT mice at 5 weeks after TAC (Figure 3.3C), in the face of lower cardiac mass in Jinx>WT
mice. Perivascular fibrosis (Figure 3.4A and 3.4B) and interstitial fibrosis (data not shown) were
similar in the two groups as was expression of Mmp9 and Col 1a (Figure 3.4C).
Platelets and platelet releasate partially restores cardiac hypertrophy after TAC in mice
lacking Munc13-4 in hematopoetic cells.
Lack of Munc13-4 impairs degranulation of NK cells, cytotoxic T lymphocytes, and platelets.
Platelets, by storing and releasing granule content with activation, may be an important source
for proteins and small molecules, such as transforming growth factor β-1 (TGFβ-1) found in αgranules and sphingosine-1-phosphate (S1P) that influence cardiac hypertrophy. Jinx platelets
do not release contents from dense granules and have severely impaired release of α-granules
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[154].

To test whether the phenotype observed in irradiated WT mice that had been

reconstituted with Jinx marrow was due to a defect in platelet secretion, a pilot study was done
by administering Jinx>WT chimers with platelets from wild-type WT mice or releasate from
thrombin-stimulated WT platelets. The administration of platelets to Jinx>WT mice partially
increased the HW: BW ratio after TAC to 8.2 ± 1.9 mg/g versus 6.9 ± 0.1 mg/g observed in
control Jinx>WT mice. The HW: BW ratios observed in Jinx>WT mice treated with platelets were
similar to those observed in WT>WT mice post-TAC (7.4 ± 0.4 mg/g versus 6.8 ± 0.8 mg/g). The
effect was not solely dependent on intact platelets, as cardiac hypertrophy following TAC was
slightly although not significantly increased by administering platelet releasate to Jinx>WT
chimers.

HW: BW ratio was 7.4 ± 0.4 mg/g in Jinx>WT mice that received releasate from

thrombin-stimulated platelets and 6.8 ± 0.8 mg/g in animals that received buffer control
(containing thrombin and hirudin). Cardiomyocyte size was slightly higher in the chimeric mice
that received platelets (301 ± 98 μm2) than those that received vehicle (289 ± 26 μm2).
Likewise, injection of platelet releasate leads to a numerical increase of cardiomyocyte size of
chimeric mice (297 ± 51 μm2 versus 244 ± 48 μm2). Together these results support a role for
Munc13-4-mediated platelet secretion in pressure-induced cardiac hypertrophy. In order to
detect the possible-existing significance, experimentsneed to be done with a large number of
animals.
TGFβ-1, which is secreted by a variety of cells, has been implicated in the development of
cardiac hypertrophy and fibrosis. Platelets store TGFβ-1 in α-granules and therefore serve as a
major source for TGFβ-1. Platelet-derived TGFβ-1 has been implicated in LVH [179].

We

established a role for Munc13-4 in the release of TGFβ-1 from platelets by measuring its release
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from isolated WT and Jinx platelets following thrombin stimulation. Thrombin but not PGE1
triggered release of TGFβ-1 from WT platelets (Figure 3.5A).

TGFβ-1 in releasate from

thrombin-stimulated Jinx platelets was 4-fold lower than WT platelets and no different than
levels observed after PGE1 treatment (Figure 3.5A).

Despite the observation that Munc13-4

was important for the release of TGFβ-1 from activated platelets in vitro, no differences in
plasma or serum level of TGFβ-1 were noted in WT and Jinx mice (Figure 3.5B). Furthermore,
plasma TGFβ-1 level were similar in WT>WT and Jinx>WT mice (Table 3.5). No difference in
plasma TGFβ-1 was observed in sham or TAC mice. Plasma levels were 1.5 ± 0.2 and 1.7 ± 0.4
ng/ml in WT>WT TAC and sham groups and 1.6 ± 0.8 and 1.3 ± 0.2 ng/ml in Jinx>WT TAC and
sham groups.

Although no differences were observed in plasma levels, TGFβ-1 downstream

signaling, as evidence by Ctgf expression, was also significantly higher in Jinx>WT than in
WT>WT mice at 7 days after TAC (Figure 3.7). Apart from TGFβ-1, S1P is also shown to induce
hypertrophic response in cardiomyocyte. Similarly, no difference in plasma S1P level was
observed between Jinx>WT and WT>WT mice (Figure 3.6).
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Table 3.1 Echocardiography parameters in before surgery
WT>WT (n=6)
Jinx>WT (n=6)
4.2 ± 0.2
4.2 ± 0.1
LVIDd (mm)
0.7 ± 0.2
0.7 ± 0.2
LVPW;d (mm)
52 ± 5
54 ± 5
EF (%)
LVID;d: left ventricular internal diameter in diastole. LVPW;d: left ventricular posterior wall
thickness in diastole. No significant differences were observed between the two groups by
Student t-test. (P ≤0.05 is considered significant.)

76

Table 3.2 Complete blood count (CBC) 7-day after surgery
WT>WT
Sham WT>WT TAC
(n=3)
(n=6)
5.5 ± 0.6
6.0 ± 1.5
WBC (K/µl)
0.7 ± 0.2
1.4 ± 0.6
NE (K/µl)
4.5 ± 0.4
4.4 ± 1.4
LY (K/µl)
0.2 ± 0.1
0.2 ± 0.1
MO (K/µl)
39.1 ± 1.1
38.9 ± 2.0
HCT (%)
45.6 ± 1.7
40.7 ± 1.2 ♦
MCV (fL)
774 ± 51
794 ± 103
PLT (K/µl)

Jinx>WT Sham
(n=3)
4.1 ± 0.7
0.5 ± 0.1
3.5 ± 0.5
0.1 ± 0.0
36.0 ± 2.0 ♦
41.1 ± 0.5 ♦
964 ± 64 ♦

Jinx>WT
(n=7)
7.3 ± 1.7 *
2.2 ± 1.1 *
4.9 ± 1.5
0.2 ± 0.1
38.1 ± 1.5
41.3 ± 0.6
914 ± 94 #

TAC

WBC: white blood cell; NE: neutrophil; LY: lymphocyte; MO: monocyte; HCT: hematocrit; MCV:
mean cell volume; PLT: platelet. ♦ P<0.05 compared to WT>WT Sham; # P<0.05 compared to
WT>WT TAC by Two-Way ANOVA.

77

Table 3.3 Complete blood count (CBC) data of chimeric mice 5-week after surgery
WT>WT
Sham WT>WT TAC
Jinx>WT
Sham Jinx>WT
(n=3)
(n=3)
(n=3)
(n=9)
14.2 ± 2.8
7.9 ± 2.6
8.2 ± 2.1
8.9 ± 3.7
WBC (K/µl)
1.1 ± 0.2
1.0 ± 0.6
0.6 ± 0.3
1.9 ± 1.6
NE (K/µl)
11.9 ± 2.4
6.5 ± 2.2 ♦
6.7 ± 1.3 ♦
6.7 ± 2.3
LY (K/µl)
0.8 ± 0.1
0.3 ± 0.2 ♦
0.7 ± 0.3
0.4 ± 0.3
MO (K/µl)
40.7 ± 1.6
41.6 ± 1.2
39.7 ± 1.2
38.4 ± 4.1
HCT (%)
10.5 ± 0.2
11.2 ± 0.7
10.5 ± 0.3
11.5 ± 1.5
Hbg (g/dL)
792 ± 73
846 ± 121
791 ± 144
1020 ± 252
PLT (K/µl)

TAC

WBC: white blood cell; NE: neutrophil; LY: lymphocyte; MO: monocyte; HCT: hematocrit; MCV:
mean cell volume; PLT: platelet. ♦ P value ≤0.05 compared to WT>WT Sham as determined by
Two-Way ANOVA.
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Table 3.4 WT mice with Jinx marrow are partially protected from LVH at five weeks after TAC
WT>WT Sham
WT>WT TAC
Jinx>WT Sham
Jinx>WT TAC
5.3 ± 0.3
7.6 ± 2.3 ♦
5.6 ± 0.6
6.7 ± 1.0
HW/BW (mg/g)
0.8 ± 0.1
1.3 ± 0.2 ♦
0.8 ± 0.1
0.9 ± 0.3*
LVPW;d (mm)
HW/BW: heart weight to body weight ratio; LVPW;d: left ventricular posterior wall thickness in
diastole. n = 3-9, ♦ P<0.05 compared to WT>WT Sham; * P<0.05 compared to WT>WT TAC by
Two-Way ANOVA.
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Table 3.5 Plasma TGFβ-1 in chimeric mice
WT>WT Sham
WT>WT TAC
1.5 ± 0.2
1.7 ± 0.4
TGFβ-1 (ng/ml)

Jinx>WT Sham
1.6 ± 0.8

Jinx>WT TAC
1.3 ± 0.2

No difference between groups by Two-Way ANOVA. (P value ≤0.05 is considered to be
significant.)
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Figure 3.1 Lack of Munc13-4 in irradiated B6 WT mice reconstituted with Jinx marrow cells.
Representative immunoblotting images demonstrate that Munc13-4 protein (120 KD) was
present in platelet lysate of WT>WT mice, but absent in Jinx>WT BMT mice. β-actin (45 KD) was
used as a loading control.
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Figure 3.2 TAC-induced cardiac hypertrophy and perivascular inflammation 7 days after surgery.
A) Heart weight to body weight ratio (HW: BW) of chimeric mice. In box-plot, the median with
10th, 25th, 75th and 90th percentiles are shown as vertical boxes with error bars. Error bars values
are column means. Animal number / group: WT>WT Sham = 8, WT>WT TAC = 11, Jinx>WT
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Sham = 7, Jinx>WT TAC = 12 *P < 0.001 by Two-Way ANOVA. B) Real-time quantitative PCR was
performed to measure mRNA of fetal genes in hearts from chimeric mice. Nppb (brain
natriuretic peptide), Myh7 (β-myosin heavy chain), and Acta1 (skeletal muscle α-actin). Values
are reports as normalized to those observed in WT>WT sham mice (set at 1). N per group:
WT>WT TAC = 6, Jinx>WT TAC = 7. *P < 0.05 by Student t-test. C) Representative images (40×)
of perivascular accumulation of T lymphocytes (CD8), macrophages (CD68), as well as
deposition of MPO and platelets. (bar = 70 μm)
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Figure 3.3 Jinx chimeric mice are protected from cardiac hypertrophy 5 weeks after TAC.
A) Representative images of heart sections stained with Masson’s trichrome from WT>WT and
Jinx>WT mice (1×, Bar = 4083 μm). B) Representative images from periodic acid-Schiff (PAS)
stained sections (40×, Bar = 70 μm). C) Quantification of cardiomyocyte area demonstrated
reduced cardiomyocyte size in Jinx>WT mice compared to WT>WT mice. Histology
quantification was done by Metamorph software. n = 4 mice / group. *P < 0.001 by Student ttest. D) Real-time quantitative PCR was performed to measure mRNA of fetal genes in hearts
from chimeric mice. Nppa (atrial natriuretic peptide), Nppb (brain natriuretic peptide), Acta1
(skeletal muscle α-actin) and Myh7 (β-myosin heavy chain). Values are reports as normalized to
those observed in WT>WT sham mice (set at 1). n = 9 mice / group. No difference were
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observed between WT>WT and Jinx>WT values after TAC by Student t-test, with P < 0.05 was
considered significant.
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Figure 3.4 Cardiac fibrosis 5 weeks after TAC.
A) Representative images of Masson’s trichrome staining (20×, Bar = 145 μm) and B)
quantification of peri-vascular fibrosis in mice 5 weeks after surgery. N / group: WT>WT Sham
= 3, WT>WT TAC = 9, Jinx>WT Sham = 3, Jinx>WT TAC = 9. Data were presented as Mean (bar)
with SEM (error bar). Data were Log-transformed for Two-Way ANOVA, *p<0.001. C) Real-time
quantitative PCR of MMP9 (Matrix Metallopeptidase 9) and Col 1a (Collagen 1). Values are
reports as normalized to those observed in WT>WT sham mice (set at 1). n= 9 mice / group. No
significant difference was observed by Student t-test.
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Figure 3.5 TGF-β1 plasma and serum levels in Jinx and B6 WT mice.
A) Platelets were isolated from WT or Jinx mice, treated with PGE1 or thrombin (IIa). Total TGFβ1 in the releasate was measured as described in Methods. B) TGF-β1 levels measured in
plasma or serum from WT and Jinx mice. No significant difference was observed between
genotypes by Student t-test, n = 3 mice / group.
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Figure 3.6 Plasma S1P levels in 7 days after TAC.
S1P plasma level was measured by mass spectrometry. Number/ group: WT>WT Sham = 5,
WT>WT TAC = 5, Jinx>WT Sham = 4, Jinx>WT TAC = 5. No difference was detected between
WT>WT and Jinx>WT mice after TAC by Two-Way ANOVA.
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Figure 3.7 TGFβ-1 signaling 7 days after TAC.
Real-time quantitative PCR was performed to measure mRNA of TGFβ-1 signaling in hearts from
chimeric mice. Tgfb1 (transforming growth factor β-1), Tgfb R2 (TGFβ-1 receptor 2) and Ctgf
(connective tissue growth factor). Values are reports as normalized to those observed in
WT>WT sham mice (set at 1). N per group: WT>WT TAC = 6, Jinx>WT TAC = 7. *P < 0.05 by
Student t-test.
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SUMMARY

To summarize the work accomplished in CHAPTER 3: Granule contents secreted in a Munc13-4dependent pathway, likely from platelets, are required for the sustained myocardial
hypertrophy induced by pressure overload. Munc13-4-dependent secretory deficiency affects
neither early inflammatory and hypertrophic response, nor later fibrotic responses.

Copyright © Fanmuyi Yang 2012
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS
SECTION 1
TAC Model We reported previously that LV pressure overload in mice elicited significant
perivascular and interstitial cardiac fibrosis at five weeks post-surgery [98]. As reported by
Hartley and colleagues, we observed impaired coronary artery function, as measured by CFR,
after TAC [95-97]. In the present study, we expanded our findings by examining the
contribution of early perivascular inflammation to coronary artery remodeling in the setting of
pressure overload. A striking and rapid accumulation of platelets, macrophages, and T
lymphocytes occurred around the left coronary vessels early post-TAC. In detail, macrophage
and T-lymphocyte accumulation was observed as early as one day after TAC and peaked at day
seven. In our previous study, late leukocyte infiltration was detected in cardiac tissue at times
up to five weeks [98]. Consistent with our data, Ying Xia et al. observed macrophage and
neutrophil infiltration at day seven after TAC and a gradual decline until day 28, at which time
levels were still higher than those in the sham group [99]. We observed platelet deposition at
three and seven days post-TAC, with no significant difference between the time points. Based
on the time course of peak inflammatory cell infiltration, we concentrated on understanding of
the events that occur early after TAC. Therefore, the effects on coronary arteries are dependent
on the early accumulation, rather than a chronic accumulation of these cells.
Suprarenal Aortic Constriction (AC): As described previously by our group and Kuwahara et al
[18,98], both transverse aortic constriction (TAC) and suprarenal aortic constriction (AC) induce
leukocyte infiltration (e.g. macrophage) in the setting of cardiac hypertrophy and fibrosis at
four to five weeks, post surgery. However, TAC does not affect peripheral blood pressure, while
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AC increases mean arterial blood pressure as early as one day post surgery. Also, most
investigators report a decline in fractional shortening (FS) at five to eight weeks after TAC;
whereas AC has been reported not to affect FS. Therefore, AC may impair diastolic dysfunction
in the setting of preserved systolic function.

Shear-Stress and Perivascular Inflammation Quantification of coronary vessel size revealed
that TAC mice had a significant increase in vessel size as compared to sham-operated animals.
In parallel, perivascular fibrosis formation significantly increased. Although the precise
mechanism(s) by which changes in flow may affect the coronary remodeling after TAC are
unknown, numerous studies have shown that flow-induced changes in shear stress can
contribute to perivascular inflammatory responses in coronary atherosclerosis and in-stent
restenosis [202,203]. In particular, PECAM-1 (CD31) serves as part of the mechanical sensor
complex regulating flow-induced vascular inflammation and remodeling [204-208]. In our
model, endothelial disturbance, as evidenced by discontinuous PECAM staining, occurred
within three days after TAC. Therefore, we hypothesize that pressure overload in the left
ventricle alters coronary flow, shear stress, and endothelial function, which subsequently
triggers platelet deposition and perivascular accumulation of inflammatory cells. The precise
molecular mechanism(s) responsible for the changes are presently not understood. Future
studies will investigate whether PECAM-1 expression or phosphorylation is altered by flow
changes resulting from TAC.
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Coronary Flow Regulation In our TAC model, Coronary dilatory dysfunction induced by LV
pressure-overload was shown by reduced coronary flow reserve (CFR). Coronary flow is tightly
regulated under physiology condition through different mechanisms. Metabolic stimulation is
one major regulator. When increased cardiac output needed, more O2 is consumed, leading to
increased CO2 production. Increased pCO2 results in more protons (eg. H+, HCO3-) which in turn
stimulate coronary vasodilation [209]. The vasodilation induced by metabolic products
increases blood flow and O2 supply and therefore is critical for maintaining the normal function
of the heart [209]. The metabolic products, such as reactive oxygen species (ROS) and
adenosine, also have vasodilatory effects [209]. Further, the decreased pO2 also serves as a
director vasodilator [209]. Another regulation mechanism is called flow-mediated regulation
which is based on the endothelium. Vascular endothelium may sense the shear alteration
through the mechanical sensors on the lumen surface, which leads to endothelial production of
either vasodilators (eg. NO, H2O2) or vasoconstrictors (eg. endothelin), working on smooth
muscle cells to elicit vasodilation or vasoconstriction [210]. Coronary flow is also regulated by
sympathetic and parasympathetic nervous systems [211].

Apart from these, recently

perivascular inflammation is also shown to be involved in the regulation of coronary blood flow
in cardiac diseases, such as myocardial ischemia reperfusion [212]. In brief, inflammatory cells
and their secretion will reduce level of the vasodilators and increase the level of
vasoconstrictors, which will lead to impaired coronary dilatory function [212]. Early perivascular
accumulation and tissue infiltration of inflammatory cells were also observed in our model,
which might be an additional factor contributing to the impaired coronary dilation.
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Platelets and Leukocyte Interaction The appearance of platelet positive staining on the luminal
surface of left coronary vessels and co-localization with leukocytes, suggested a role for
platelets in coronary artery remodeling in response to pressure overload. Previous literature
has reported that platelets dynamically influence the immune system through CD154 (CD40L)
mediated interactions with CD40 on T and B lymphocytes [88,213,214]. Moreover, platelets
enhance IL-10 expression by immature dendritic cells which in turn promotes the proliferation
of naive T-cells [198]. We report that pericoronary T lymphocytes accumulation was
significantly reduced in thrombocytopenic mice, suggesting a potential role for platelets in T
lymphocytes recruitment, either through direct contact or indirectly through mediators. Our
immunodepletion protocol resulted in thrombocytopenia for up to one week, supporting a role
for platelets in this time frame. Because platelet deposition and lymphocyte accumulation
appeared as early as 24 hours after TAC (data not shown and Figure 2.2A), we are unable to
establish whether platelet deposition is the initiating event or whether it occurs in response to
inflammatory changes and serves to perpetuate the inflammatory response.

Induced-Thrombocytopenia Exposure to high shear stress enables platelets to elicit IL-10
production from dendritic cells [198]. The change in flow following TAC may trigger a similar
response from platelets and contribute to IL-10 expression and T cell accumulation, which
would account for lower levels of IL-10 and T cells in thrombocytopenic animals. The
subsequent increase in SMC α-actin in thrombocytopenic animals could reflect an impact of
these events on either the proliferative or inflammatory profile of SMC. Immune-mediated
thrombocytopenia is followed by reactive thrombocytosis. Therefore, in the anti-GPIbα IgG94

treated mice, it is possible that a subsequent increase in platelet count is influencing
subsequent events, although given the propensity for platelet surfaces to passivate over time;
this seems less likely than an effect of the initial thrombocytopenia. However, it is still not know
how reactive thrombocytosis may contribute.

TAC-induced platelet accumulation was

observed at three and seven days and thrombocytopenia elicited by the GPIb-α antibody is
sustained for up to one week. We do not know if reactive thrombocytosis promotes late
platelet events, although we do not detect differences in inflammatory cells at the late time
points. In addition, reactive thrombocytosis can be accompanied by platelet dysfunction, and
the impact of either elevated platelets counts or platelet dysfunction is not elucidated in this
model.
The Role of T lymphocytes in Cardiac Remodeling Previous reports have implicated T
lymphocytes in hypertensive cardiovascular diseases [81]. Our observations in Rag1-/- mice
additionally suggest a role for lymphocytes in influencing remodeling by limiting neointima
formation and perivascular fibrosis following TAC. Interestingly, despite the increase in fibrosis,
CFR was improved in the absence of lymphocytes. These effects are likely mediated largely by
T-cells, as we were unable to detect changes in B-cell accumulation in cardiac tissue post-TAC.
In addition, at baseline, the collagen content in Rag1-/- mice was lower, supporting a role for
lymphocytes in extracellular matrix dynamics under basal conditions. Others have reported
lower basal vascular superoxide levels in Rag1-/- mice [81]. Vascular superoxide correlates with
and may influence fibrotic remodeling, and may underlie the differences in the perivascular
collagen content we observed in the sham-operated Rag1-/- mice.
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The subsets of T cells involved in TAC-induced remodeling responses are presently unknown.
Subsets of T lymphocytes appear to differentially influence pathological remodeling. For
example, whereas CD1d-positive natural killer cells seem to promote the development of
neointima after vascular injury in a carotid collar model [69], CD4+CD25+ regulatory T cells
adoptive transfer not only reduces angiotensin-induced early infiltration of inflammatory cells
in cardiac tissue, but also blunts the subsequent development of cardiac hypertrophy, fibrosis
formation, and arrhythmogenic potential [74]. Moreover, a balance between T helper 1 (Th1)
and Th2 cells has been proposed to contribute to coronary and myocardial inflammation, and
may be essential for cardiac extracellular matrix remodeling [70,71,215]. In an immune
modulation mouse model, induction of Th1 responses led to increased collagen deposition,
more LV stiffness, and down-regulation of MMP-9 and MMP-13 gene expression [71].
The Role of IL-10 in TAC In the TAC model, we observed a significant increase in expression of
IL-10 in cardiac tissue between days one and seven post-TAC. IL-10 is a Th2 cytokine produced
by many cell types, including macrophages and T helper 2 cells. IL-10 signals through the
JAK/STAT3 pathway to modulate the expression of certain pro-inflammatory molecules and
usually plays an important role in anti-inflammatory responses. For example, IL-10 is able to
attenuate the NF-κB pathway through inhibition of IKK or NF-κB nuclear translocation [216].
Also, IL-10 can suppress vascular smooth muscle cell activation and proliferation and thereby
attenuate neointima formation [35,217,218]. Recently, Krishnamurthy et al. reported that IL-10
treatment reduced macrophage accumulation and inflammatory cytokine expression, leading
to attenuated left ventricular remodeling after myocardial infarction [219]. In keeping with
these observations, bone marrow, mononuclear cell-derived IL-10 attenuates T cell infiltration
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and cardiac remodeling after myocardial infarction, which prevents cardiac dysfunction [220].
In our model, increased expression of IL-10 parallels T lymphocyte infiltration early after TAC
and may serve to attenuate the inflammatory responses and suppress SMC proliferation.
Indeed, lower IL-10 levels correlate with increased medial hypertrophy in thrombocytopenic
mice after TAC. Likewise, IL-10-/- mice display normal cardiac hypertrophy, but exaggerated
vascular fibrotic remodeling post-TAC.

The results presented above indicate that platelets may influence coronary remodeling and
perivascular fibrosis after TAC through recruitment of T-lymphocytes and stimulating IL-10dependent signaling. In addition, platelets may have direct effects on coronary fibroblast
function by releasing mediators that phenotypically modify fibroblasts. Indeed, we found that
platelet releasate directly stimulates cardiac fibroblasts to increase the MMP9 expression and
upregulate TGFβ-1 signaling. Platelets contain large storage of TGFβ-1 in their α-granules that
could potentially activate fibroblasts and increase MMP production. Whether platelet-triggered
MMP9 production attenuates or otherwise affects fibrosis remains to be established.

In summary, perivascular inflammation proceeds and accompanies coronary remodeling in the
setting of pressure overload. Platelets, macrophages and lymphocytes accumulate along and
around the coronary arteries early after TAC, accompanied by up-regulation of IL-10 expression
in the myocardial tissue. Following TAC, the vessels undergo positive remodeling that is
accompanied by extensive perivascular fibrosis. Surprisingly, both platelets and lymphocytes
appear to play a protective role in minimizing remodeling and fibrosis. Our data are consistent
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with a model in which platelets influence lymphocyte recruitment -- either by direct interaction
or indirectly through stimulation of IL-10 (and/or other mediators) -- by recruited or resident
cells. The IL-10 may act to suppress ongoing inflammation and limit perivascular fibrosis. Similar
mechanisms may occur in settings of hypertension and our model may have particular
relevance to hypertensive urgency, in which acute and dramatic elevations in blood pressure
may be associated with a disruption in endothelial function and a pro-inflammatory state in
coronary arteries. The optimal strategy for minimizing coronary artery damage in the setting of
acute elevations in pressure remains to be determined.
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SECTION 2
We found that mice lacking the Rab27 effector protein Munc13-4 in bone marrow cells
(Jinx>WT) were partially protected from the development of LVH at five weeks after pressure
overload. The lack of hypertrophy was due to smaller cardiomyocyte size in mice with Jinx
bone marrow cells, indicating protection from cardiomyocyte hypertrophy. The initial response
to pressure overload at seven days was not detectably different from mice with normal bone
marrow (WT>WT), in that the mice developed cardiac hypertrophy, an inflammatory response,
and upregulation of cardiac fetal gene expression in response to the mechanical stress of
pressure. Our results imply that there is a role for granule secretion in propagating the
hypertrophy response that is initiated by pressure overload.
Cardiac Endogenous Negative Regulators of Hypertrophy Granules in hematopoietic cells
contain a variety of cytokines, with many functions including promoting and inhibiting
angiogenesis, fibrosis, thrombosis, and migration that could affect cardiac remodeling. The
reduced hypertrophy in the Jinx chimeric mice could be due to loss of positive regulators from
hematopoietic cells. Alternatively, factors that suppress endogenous negative regulators of
cardiac hypertrophy may not be released. Two major types of endogenous negative regulators
have been reported [221]: group I negative regulators (i.e. glycogen synthase kinase - 3) which
are constitutively active during physiological conditions and inhibited by hypertrophic stimuli
and promote hypertrophy; group II (i.e. ICER) regulators that are upregulated upon
hypertrophic stimuli and counteract the response. Negative regulators belonging to both
groups, such as thioredoxin (Trx1), have also been reported. It has been shown that Trx1 is
upregulated in pressure-overload [222]. It is possible that component of hematopoietic cell
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releasate influences cardiomyocyte expression of a group 2 regulator. Whether interaction
between inflammatory cells and cardiomyocytes inhibits the expression of cardiac endogenous
regulators remains to be determined. It is also unclear which factors they are. Still, in terms of
the identified pathways through which the endogenous regulators play their roles, the potential
suppressors secreted by hematopoietic cells, if they exist, may directly interact with
endogenous negative regulators, or work by influencing PKA pathway or the intracellular
oxidative stress [221].
Platelet-Derived Potential Mediators of Cardiac Hypertrophy Platelets and to a lesser extent
platelet releasate were able to promote cardiac hypertrophy mice lacking the Rab27 effector
protein Munc13-4 in bone marrow cells. These finding indicate that factors present in platelet
granules and likely secreted in a Munc13-4-dependent manner influence cardiomyocyte
hypertrophy. The loss of Munc13-4 results in defects in platelet α-granules, dense granules and
lysosomes.

Several possible candidate mediators that are released from platelets and

reportedly promote cardiac hypertrophy include TGFβ1 [179], sphingosine-1-phosphate, and
serotonin.

Platelets contribute to plasma TGFβ-1 and platelet-derived TGFβ1 influences

cardiac remodeling after TAC [179]. Our findings indicate that Munc13-4 is important for
thrombin-mediated release of TGFβ-1 from platelets. In response to thrombin, isolated WT but
not Jinx platelets release substantial TGFβ-1. However, no differences were observed in TGFβ-1
levels in serum or plasma levels from Jinx and B6 mice. TGFβ-1 secretion from platelets may
occur through multiple pathways. Platelet α-granules, where TGFβ-1 is stored, may be
heterogeneous subpopulations that can be differentially released [105,223]. Thus, stimuli
other than thrombin may have less dependency on Munc13-4. We were unable to detect an
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effect of TAC on plasma levels of TGFβ-1 at 7 days after surgery. Likewise no difference in
plasma levels of S1P, another putative regulator of cardiomyocytes, was detected in Jinx and B6
chimeric mice 7 days after surgery. It is possible that there are differences at early time points,
because peri-coronary deposition of platelets occurs as early as 24 hours after TAC (previous
published data). Additionally, local microenvironmental effects of those mediators, rather than
the systemic circulating ones, may be important for the hypertrophic response. Finally, while
our studies implicate platelets as regulators of cardiac hypertrophy, the phenotype observed in
mice lacking Munc13-4 could be due to a lack of cargo release from other hematopoietic cells,
which influence cardiomyocytes.
As I have mentioned in Chapter 1 Section 1, elevated platelet activation has been observed in
series of cardiovascular diseases. Therefore, the anti-thrombotic therapies, in particular the
anti-platelet therapy, might not only benefit the patients through preventing blood clot
formation but also through reducing the secretion of hypertrophy-promoting factors from
platelets.
Reprogramming of Fetal Genes, such as ANP, BNP, β-MHC, α-skeletal actin, occurs during
cardiac hypertrophy. Seven days after TAC, fetal gene expression was upregulated in both
Jinx>WT and WT>WT mice. Intriguingly, the fetal gene expression profile persisted in mice with
Jinx marrow at 5 weeks, under conditions where they did not display progression of cardiac
hypertrophy. Previous studies of unloaded hypertrophic hearts reported that the unloading did
not alter fetal gene expression, leading to speculation that opposite stimuli may elicit similar
patterns of gene expression [224]. In our study, the continued presence of pressure overload
may be triggering fetal gene expression, but is not sufficient to promote continued
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hypertrophy, which requires factors released from hematopoietic cells. In keeping with these
observations, no difference in either inflammatory cell infiltration or the fibrotic responses was
observed in mice lacking Munc13-4 in marrow cells. These findings suggest that fibrosis and
myocardial hypertrophy are distinctly regulated, at least later in the course of the disease.
In summary, factors secreted from marrow-derived cells in a Munc13-4-dependent manner are
important for maintaining the hypertrophic response of cardiomyocytes in response to
pressure-overload. Platelet cargo release accounts for at least some of the effect. Thus,
inhibition of platelet granule secretion might represent an effective way to reduce cardiac
hypertrophy.
Future Directions In terms of our data, further study to discover the potential mediators or
signaling pathways accounting for the phenotype we observed is very important. We would
replace the complicated animal models we used in our preliminary study by a cultured
cardiomyocyte cell line (H9C2). As positive control, cells will be treated with the proposed
mediators (TGFβ-1, S1P and serotonin) individually thus generating hypertrophy phenotype.
The cells will then be treated with the properly titrated WT platelet releasate to see if it can
induce hypertrophic responses, or with Jinx platelet releasate to see if the hypertrophic
response is absent due to Munc13-4 deficiency.
Hypertrophic responses will be studied by immunostaining (cardiomyocyte morphology) and
quantitative PCR (fetal genes’ expression). If we see attenuated myocyte hypertrophy in
response to Jinx platelet releasate compared to WT releasate, we will further elucidate the
potential mediators using platelets deficient of those mediators either through genetical
modification (i.e. platelets from TGFβ-1

-/-

mice or sphingosine kinase 1(SphK1)
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-/-

mice) or

pharmacological manipulation (i.e. neutralizing antibody to TGFβ-1). If we see less hypertrophy
in treatment of platelet releasate deficient of certain proposed mediator, we will repeat the
experiment in vivo by injecting these platelets or their releasate into Jinx chimeric mice to see
whether Munc13-4 deficiency diminishes the recovered hypertrophy induced by WT platelet
reinjection.
If we do not see hypertrophic response with treatment of WT platelet releasate, it might
suggest the restored cardiac hypertrophy in vivo is due to indirect effects of other inflammatory
cells which can be influenced by platelet secretion. To address this question, we can quantify
the blood cell components of Jinx chimeric mice with platelet injection at different time points
by complete blood count. To be more accurate, flow cytometry can be used to identify specific
inflammatory cell groups. If we still see hypertrophic responses with treatment of Jinx platelet
releasate, it might indicate that secretion of hypertrophic mediators from platelets is not
prevented by Munc13-4 deficiency. Therefore, attenuated cardiac hypertrophy observed in Jinx
chimeric mice could be due to secretion defects from other cell types which are regulated by
platelet secretion.
More mediators need to be explored if we did not see less hypertrophy in groups treated with
platelet releasate deficient of the proposed mediators. Luminex assay could be performed to
measure plasma or cardiac level of potential pro-hypertrophic factors in chimeric mice which
could be secreted from platelets and other hematopoietic cells. Gene microarray could also be
performed to measure the expression of cardiac endogenous negative regulators. Due to the
distinct temporal distribution of gene expression, several representative time points need to be
chosen.
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